Forside  
Velg data du ønsker med i utskriften
Tittel Versjon Status
IS-nr ISBN
Revisjonsdato Publiseringsdato
Utgiver(e) Publikasjonstype
  • Norsk tittel - Nasjonalt handlingsprogram med retningslinjer for gynekologisk kreft
  • Engelsk tittel -
  • Versjon - 2
  • Status - Publisert
  • IS-nr - 2854
  • ISBN - 978-82-8081-607-8
  • DOI -
  • Revisjonsdato - 20.05.2020
  • Neste revisjon -
  • Publikasjonsdato - 19.09.2016
  • Utløpsdato -
  • Utgiver(e) - Helsedirektoratet
  • Redaktør -
  • Publikasjonstype - Nasjonale retningslinjer
 
  1. Pakkeforløp for livmorkreft rev. utg. Oslo: Helsedirektoratet; 2016. IS-2353. Tilgjengelig fra: https://helsedirektoratet.no/retningslinjer/pakkeforlop-for-livmorkreft 

  2. Pakkeforløp for eggstokkreft. rev. utg. Oslo: Helsedirektoratet; 2016. IS-2352. Tilgjengelig fra: https://helsedirektoratet.no/retningslinjer/pakkeforlop-for-eggstokkreft 

  3. Pakkeforløp for livmorhalskreft rev. utg. Oslo: Helsedirektoratet; 2016. IS-2354. Tilgjengelig fra: https://helsedirektoratet.no/retningslinjer/pakkeforlop-for-livmorhalskreft 

  4. Elit L, Chambers A, Fyles A, Covens A, Carey M, Fung MF. Systematic review of adjuvant care for women with Stage I ovarian carcinoma. Cancer 2004;101(9):1926–35.

  5. Colombo N, Van Gorp T, Parma G, Amant F, Gatta G, Sessa C, et al. Ovarian cancer. Crit Rev Oncol Hematol 2006;60(2):159–79.

  6. Larsen IK, red. Cancer in Norway 2012: cancer incidence, mortality, survival and prevalence in Norway. Oslo: Cancer Registry of Norway; 2014. Tilgjengelig fra: https://www.kreftregisteret.no/globalassets/cancer-in-norway/2012/cin_2012-web.pdf 

  7. Wijnen J, de Leeuw W, Vasen H, van der Klift H, Moller P, Stormorken A, et al. Familial endometrial cancer in female carriers of MSH6 germline mutations. Nat Genet 1999;23(2):142–4.

  8. Kvåle G, Heuch I, Ursin G. Reproductive factors and risk of cancer of the uterine corpus: a prospective study. Cancer Res 1988;48(21):6217–21.

  9. Pike MC, Peters RK, Cozen W, Probst-Hensch NM, Felix JC, Wan PC, et al. Estrogen-progestin replacement therapy and endometrial cancer. J Natl Cancer Inst 1997;89(15):1110–6.

  10. Weiderpass E, Baron JA, Adami HO, Magnusson C, Lindgren A, Bergstrom R, et al. Low-potency oestrogen and risk of endometrial cancer: a case-control study. Lancet 1999;353(9167):1824–8.

  11. Committee on Gynecologic Practice. Tamoxifen and uterine cancer. Washington, DC: American College of Obstetricians and Gynecologists; 2014. Committee Opinion no 601. Tilgjengelig fra: http://www.acog.org/-/media/Committee-Opinions/Committee-on-Gynecologic-Practice/​co601.pdf?dmc=1&ts=20150203T1931301384 

  12. Kinkel K, Kaji Y, Yu KK, Segal MR, Lu Y, Powell CB, et al. Radiologic staging in patients with endometrial cancer: a meta-analysis. Radiology 1999;212(3):711–8.

  13. Dijkhuizen FP, Mol BW, Brolmann HA, Heintz AP. The accuracy of endometrial sampling in the diagnosis of patients with endometrial carcinoma and hyperplasia: a meta-analysis. Cancer 2000;89(8):1765–72.

  14. Goldchmit R, Katz Z, Blickstein I, Caspi B, Dgani R. The accuracy of endometrial Pipelle sampling with and without sonographic measurement of endometrial thickness. Obstet Gynecol 1993;82(5):727–30.

  15. Stefansson IM, Salvesen HB, Immervoll H, Akslen LA. Prognostic impact of histological grade and vascular invasion compared with tumour cell proliferation in endometrial carcinoma of endometrioid type. Histopathology 2004;44(5):472–9.

  16. Pecorelli S. Revised FIGO staging for carcinoma of the vulva, cervix, and endometrium. Int J Gynaecol Obstet 2009;105(2):103–4.

  17. Koornstra JJ, Mourits MJ, Sijmons RH, Leliveld AM, Hollema H, Kleibeuker JH. Management of extracolonic tumours in patients with Lynch syndrome. Lancet Oncol 2009;10(4):400–8.

  18. Dowty JG, Win AK, Buchanan DD, Lindor NM, Macrae FA, Clendenning M, et al. Cancer risks for MLH1 and MSH2 mutation carriers. Hum Mutat 2013;34(3):490–7.

  19. Barrow E, Robinson L, Alduaij W, Shenton A, Clancy T, Lalloo F, et al. Cumulative lifetime incidence of extracolonic cancers in Lynch syndrome: a report of 121 families with proven mutations. Clin Genet 2009;75(2):141–9.

  20. Møller P, Seppälä TT, Bernstein I, Holinski-Feder E, Sala P, Gareth Evans D, et al. Cancer risk and survival in path_MMR carriers by gene and gender up to 75 years of age: a report from the Prospective Lynch Syndrome Database. Gut 2018;67(7):1306–16.

  21. Aaltonen L, Johns L, Järvinen H, Mecklin JP, Houlston R. Explaining the familial colorectal cancer risk associated with mismatch repair (MMR)-deficient and MMR-stable tumors. Clin Cancer Res 2007;13(1):356–61.

  22. Larsen IK, red. Cancer in Norway 2017: cancer incidence, mortality, survival and prevalence in Norway. Oslo: Cancer Registry of Norway; 2018. Tilgjengelig fra: https://www.kreftregisteret.no/globalassets/cancer-in-norway/2017/cin-2017.pdf 

  23. Goodfellow PJ, Billingsley CC, Lankes HA, Ali S, Cohn DE, Broaddus RJ, et al. Combined Microsatellite Instability, MLH1 Methylation Analysis, and Immunohistochemistry for Lynch Syndrome Screening in Endometrial Cancers From GOG210: An NRG Oncology and Gynecologic Oncology Group Study. J Clin Oncol 2015;33(36):4301–8.

  24. Banno K, Yanokura M, Kobayashi Y, Kawaguchi M, Nomura H, Hirasawa A, et al. Endometrial cancer as a familial tumor: pathology and molecular carcinogenesis (review). Current genomics 2009;10(2):127–32.

  25. Wang Y, Wang Y, Li J, Cragun J, Hatch K, Chambers SK, et al. Lynch syndrome related endometrial cancer: clinical significance beyond the endometrium. J Hematol Oncol 2013;6:22.

  26. Bonadona V, Bonaïti B, Olschwang S, Grandjouan S, Huiart L, Longy M, et al. Cancer risks associated with germline mutations in MLH1, MSH2, and MSH6 genes in Lynch syndrome. JAMA 2011;305(22):2304–10.

  27. Genetic/Familial High-Risk Assessment: Colorectal. [NCCN Guideline]. Version 1. Plymouth Meeting, PA: National Comprehensive Cancer Network; 2016.

  28. Mills AM, Liou S, Ford JM, Berek JS, Pai RK, Longacre TA. Lynch syndrome screening should be considered for all patients with newly diagnosed endometrial cancer. Am J Surg Pathol 2014;38(11):1501–9.

  29. Hampel H, Panescu J, Lockman J, Sotamaa K, Fix D, Comeras I, et al. Comment on: Screening for Lynch Syndrome (Hereditary Nonpolyposis Colorectal Cancer) among Endometrial Cancer Patients. Cancer Res 2007;67(19):9603.

  30. Schmeler KM, Lynch HT, Chen LM, Munsell MF, Soliman PT, Clark MB, et al. Prophylactic surgery to reduce the risk of gynecologic cancers in the Lynch syndrome. N Engl J Med 2006;354(3):261–9.

  31. Walker JL, Piedmonte MR, Spirtos NM, Eisenkop SM, Schlaerth JB, Mannel RS, et al. Laparoscopy compared with laparotomy for comprehensive surgical staging of uterine cancer: Gynecologic Oncology Group Study LAP2. J Clin Oncol 2009;27(32):5331–6.

  32. Colombo N, Creutzberg C, Amant F, Bosse T, González-Martin A, Ledermann J, et al. ESMO-ESGO-ESTRO Consensus Conference on Endometrial Cancer: Diagnosis, Treatment and Follow-up. Int J Gynecol Cancer 2016;26(1):2–30.

  33. Pilarski R, Stephens JA, Noss R, Fisher JL, Prior TW. Predicting PTEN mutations: an evaluation of Cowden syndrome and Bannayan-Riley-Ruvalcaba syndrome clinical features. J Med Genet 2011;48(8):505–12.

  34. Heald B, Mester J, Rybicki L, Orloff MS, Burke CA, Eng C. Frequent gastrointestinal polyps and colorectal adenocarcinomas in a prospective series of PTEN mutation carriers. Gastroenterology 2010;139(6):1927–33.

  35. Rose PG. Endometrial carcinoma. N Engl J Med 1996;335(9):640–9.

  36. Galaal K, Bryant A, Fisher AD, Al-Khaduri M, Kew F, Lopes AD. Laparoscopy versus laparotomy for the management of early stage endometrial cancer. Cochrane Database Syst Rev 2012;(9):Cd006655.

  37. Chan JK, Cheung MK, Huh WK, Osann K, Husain A, Teng NN, et al. Therapeutic role of lymph node resection in endometrioid corpus cancer: a study of 12,333 patients. Cancer 2006;107(8):1823–30.

  38. May K, Bryant A, Dickinson HO, Kehoe S, Morrison J. Lymphadenectomy for the management of endometrial cancer. Cochrane Database Syst Rev 2010;(1):Cd007585.

  39. Creasman WT, Morrow CP, Bundy BN, Homesley HD, Graham JE, Heller PB. Surgical pathologic spread patterns of endometrial cancer. A Gynecologic Oncology Group Study. Cancer 1987;60(8 Suppl):2035–41.

  40. Johnson N, Bryant A, Miles T, Hogberg T, Cornes P. Adjuvant chemotherapy for endometrial cancer after hysterectomy. Cochrane Database Syst Rev 2011;(10):Cd003175.

  41. Hogberg T, Signorelli M, de Oliveira CF, Fossati R, Lissoni AA, Sorbe B, et al. Sequential adjuvant chemotherapy and radiotherapy in endometrial cancer--results from two randomised studies. Eur J Cancer 2010;46(13):2422–31.

  42. Aalders J, Abeler V, Kolstad P, Onsrud M. Postoperative external irradiation and prognostic parameters in stage I endometrial carcinoma: clinical and histopathologic study of 540 patients. Obstet Gynecol 1980;56(4):419–27.

  43. Creutzberg CL, van Putten WL, Koper PC, Lybeert ML, Jobsen JJ, Warlam-Rodenhuis CC, et al. Surgery and postoperative radiotherapy versus surgery alone for patients with stage-1 endometrial carcinoma: multicentre randomised trial. PORTEC Study Group. Post Operative Radiation Therapy in Endometrial Carcinoma. Lancet 2000;355(9213):1404–11.

  44. Kong A, Johnson N, Kitchener HC, Lawrie TA. Adjuvant radiotherapy for stage I endometrial cancer. Cochrane Database Syst Rev 2012;(4):Cd003916.

  45. Martin-Hirsch PP, Bryant A, Keep SL, Kitchener HC, Lilford R. Adjuvant progestagens for endometrial cancer. Cochrane Database Syst Rev 2011;(6):Cd001040.

  46. Vergote I, Kjørstad K, Abeler V, Kolstad P. A randomized trial of adjuvant progestagen in early endometrial cancer. Cancer 1989;64(5):1011–6.

  47. Njølstad TS, Trovik J, Hveem TS, Kjæreng ML, Kildal W, Pradhan M, et al. DNA ploidy in curettage specimens identifies high-risk patients and lymph node metastasis in endometrial cancer. Br J Cancer 2015;112(10):1656–64.

  48. Salvesen HB, Haldorsen IS, Trovik J. Markers for individualised therapy in endometrial carcinoma. Lancet Oncol 2012;13(8):e353–61.

  49. Trovik J, Wik E, Werner HM, Krakstad C, Helland H, Vandenput I, et al. Hormone receptor loss in endometrial carcinoma curettage predicts lymph node metastasis and poor outcome in prospective multicentre trial. Eur J Cancer 2013;49(16):3431–41.

  50. ASTEC study group, Kitchener H, Swart AM, Qian Q, Amos C, Parmar MK. Efficacy of systematic pelvic lymphadenectomy in endometrial cancer (MRC ASTEC trial): a randomised study. Lancet 2009;373(9658):125–36.

  51. Trimble EL, Kosary C, Park RC. Lymph node sampling and survival in endometrial cancer. Gynecol Oncol 1998;71(3):340–3.

  52. Vale CL, Tierney J, Bull SJ, Symonds PR. Chemotherapy for advanced, recurrent or metastatic endometrial carcinoma. Cochrane Database Syst Rev 2012;(8):Cd003915.

  53. Abeler VM, Kjørstad KE. Endometrial adenocarcinoma in Norway. A study of a total population. Cancer 1991;67(12):3093–103.

  54. Salvesen HB, Iversen OE, Akslen LA. Prognostic significance of angiogenesis and Ki-67, p53, and p21 expression: a population-based endometrial carcinoma study. J Clin Oncol 1999;17(5):1382–90.

  55. Iversen OE. Flow cytometric deoxyribonucleic acid index: a prognostic factor in endometrial carcinoma. Am J Obstet Gynecol 1986;155(4):770–6.

  56. Salvesen HB, Akslen LA, Iversen T, Iversen OE. Recurrence of endometrial carcinoma and the value of routine follow up. Br J Obstet Gynaecol 1997;104(11):1302–7.

  57. Lifestyle and Empowerment Techniques in Survivorship of Gynecologic Oncology (LETSGO) [pågående studie]. 2018-. NCT03453788. Tilgjengelig fra: https://clinicaltrials.gov/ct2/show/NCT03453788 

  58. Fung-Kee-Fung M, Dodge J, Elit L, Lukka H, Chambers A, Oliver T, et al. Follow-up after primary therapy for endometrial cancer. Toronto (ON): Program in Evidence-based Care og Cancer Care Ontario; 2006. Evidence-based Series 4–9 IN REVIEW. Tilgjengelig fra: https://www.cancercare.on.ca/common/pages/UserFile.aspx?serverId=6&path=/File%20Database/CCO%20Files/PEBC/pebc4-9f.pdf 

  59. Peng X, Fu J, Lina H. Hormone replacement therapy for women previously treated for endometrial cancer [Protocol]. Cochrane Database Syst Rev 2010;(11):CD008830.

  60. Moore TD, Phillips PH, Nerenstone SR, Cheson BD. Systemic treatment of advanced and recurrent endometrial carcinoma: current status and future directions. J Clin Oncol 1991;9(6):1071–88.

  61. Amant F, Moerman P, Neven P, Timmerman D, Van Limbergen E, Vergote I. Endometrial cancer. Lancet 2005;366(9484):491–505.

  62. Colombo N, Preti E, Landoni F, Carinelli S, Colombo A, Marini C, et al. Endometrial cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2013;24 Suppl 6:vi33–8.

  63. Uterussarkom I: Veileder i gynekologisk onkologi. Trondheim/Bergen/Oslo: Norsk gynekologisk forening; 2009. Tilgjengelig fra: https://www.legeforeningen.no/contentassets/04d0b3c134ac4b12aa1a03c3a2666585/veileder-i-gynekologisk-onkologi-2009.pdf 

  64. Palliasjon i kreftomsorgen: nasjonalt handlingsprogram med retningslinjer for palliasjon i kreftomsorgen Oslo: Helsedirektoratet; 2015. IS-2285. Tilgjengelig fra: https://www.helsedirektoratet.no/retningslinjer/palliasjon-i-kreftomsorgen-handlingsprogram

  65. Kurman RJ, Kaminski PF, Norris HJ. The behavior of endometrial hyperplasia. A long-term study of "untreated" hyperplasia in 170 patients. Cancer 1985;56(2):403–12.

  66. Ørbo A, Arnes M, Hancke C, Vereide AB, Pettersen I, Larsen K. Treatment results of endometrial hyperplasia after prospective D-score classification: a follow-up study comparing effect of LNG-IUD and oral progestins versus observation only. Gynecol Oncol 2008;111(1):68–73.

  67. Owings RA, Quick CM. Endometrial intraepithelial neoplasia. Arch Pathol Lab Med 2014;138(4):484–91.

  68. Ørbo A, Baak JP, Kleivan I, Lysne S, Prytz PS, Broeckaert MA, et al. Computerised morphometrical analysis in endometrial hyperplasia for the prediction of cancer development. A long-term retrospective study from northern Norway. J Clin Pathol 2000;53(9):697–703.

  69. Trimble CL, Kauderer J, Zaino R, Silverberg S, Lim PC, Burke JJ, 2nd, et al. Concurrent endometrial carcinoma in women with a biopsy diagnosis of atypical endometrial hyperplasia: a Gynecologic Oncology Group study. Cancer 2006;106(4):812–9.

  70. Kurman RJ, Carcangiu ML, Herrington CS, Young RH. WHO classification of Tumours of Female Reproductive Organs. 4. utg. Lyon: IARC; 2014.

  71. Zaino RJ, Kauderer J, Trimble CL, Silverberg SG, Curtin JP, Lim PC, et al. Reproducibility of the diagnosis of atypical endometrial hyperplasia: a Gynecologic Oncology Group study. Cancer 2006;106(4):804–11.

  72. Bergeron C, Nogales FF, Masseroli M, Abeler V, Duvillard P, Müller-Holzner E, et al. A multicentric European study testing the reproducibility of the WHO classification of endometrial hyperplasia with a proposal of a simplified working classification for biopsy and curettage specimens. Am J Surg Pathol 1999;23(9):1102–8.

  73. Kendall BS, Ronnett BM, Isacson C, Cho KR, Hedrick L, Diener-West M, et al. Reproducibility of the diagnosis of endometrial hyperplasia, atypical hyperplasia, and well-differentiated carcinoma. Am J Surg Pathol 1998;22(8):1012–9.

  74. Baak JP, Mutter GL, Robboy S, van Diest PJ, Uyterlinde AM, Orbo A, et al. The molecular genetics and morphometry-based endometrial intraepithelial neoplasia classification system predicts disease progression in endometrial hyperplasia more accurately than the 1994 World Health Organization classification system. Cancer 2005;103(11):2304–12.

  75. Baak JP, Nauta JJ, Wisse-Brekelmans EC, Bezemer PD. Architectural and nuclear morphometrical features together are more important prognosticators in endometrial hyperplasias than nuclear morphometrical features alone. J Pathol 1988;154(4):335–41.

  76. Baak JP, Ørbo A, van Diest PJ, Jiwa M, de Bruin P, Broeckaert M, et al. Prospective multicenter evaluation of the morphometric D-score for prediction of the outcome of endometrial hyperplasias. Am J Surg Pathol 2001;25(7):930–5.

  77. Baak JP, Wisse-Brekelmans EC, Fleege JC, van der Putten HW, Bezemer PD. Assessment of the risk on endometrial cancer in hyperplasia, by means of morphological and morphometrical features. Pathol Res Pract 1992;188(7):856–9.

  78. Dunton CJ, Baak JP, Palazzo JP, van Diest PJ, McHugh M, Widra EA. Use of computerized morphometric analyses of endometrial hyperplasias in the prediction of coexistent cancer. Am J Obstet Gynecol 1996;174(5):1518–21.

  79. Mutter GL. Diagnosis of premalignant endometrial disease. J Clin Pathol 2002;55(5):326–31.

  80. Mutter GL, Baak JP, Crum CP, Richart RM, Ferenczy A, Faquin WC. Endometrial precancer diagnosis by histopathology, clonal analysis, and computerized morphometry. J Pathol 2000;190(4):462–9.

  81. Mutter GL, Baak JP, Fitzgerald JT, Gray R, Neuberg D, Kust GA, et al. Global expression changes of constitutive and hormonally regulated genes during endometrial neoplastic transformation. Gynecol Oncol 2001;83(2):177–85.

  82. Ørbo A, Vereide A, Arnes M, Pettersen I, Straume B. Levonorgestrel-impregnated intrauterine device as treatment for endometrial hyperplasia: a national multicentre randomised trial. BJOG 2014;121(4):477–86.

  83. Vereide AB, Arnes M, Straume B, Maltau JM, Ørbo A. Nuclear morphometric changes and therapy monitoring in patients with endometrial hyperplasia: a study comparing effects of intrauterine levonorgestrel and systemic medroxyprogesterone. Gynecol Oncol 2003;91(3):526–33.

  84. Garuti G, Mirra M, Luerti M. Hysteroscopic view in atypical endometrial hyperplasias: A correlation with pathologic findings on hysterectomy specimens. J Minim Invasive Gynecol 2006;13(4):325–30.

  85. Hecht JL, Ince TA, Baak JP, Baker HE, Ogden MW, Mutter GL. Prediction of endometrial carcinoma by subjective endometrial intraepithelial neoplasia diagnosis. Mod Pathol 2005;18(3):324–30.

  86. Mutter GL, Zaino RJ, Baak JP, Bentley RC, Robboy SJ. Benign endometrial hyperplasia sequence and endometrial intraepithelial neoplasia. Int J Gynecol Pathol 2007;26(2):103–14.

  87. Crissman JD, Azoury RS, Barnes AE, Schellhas HF. Endometrial carcinoma in women 40 years of age or younger. Obstet Gynecol 1981;57(6):699–704.

  88. Bjarnason K, Cerin A, Lindgren R, Weber T. Adverse endometrial effects during long cycle hormone replacement therapy. Scandinavian Long Cycle Study Group. Maturitas 1999;32(3):161–70.

  89. Furness S, Roberts H, Marjoribanks J, Lethaby A. Hormone therapy in postmenopausal women and risk of endometrial hyperplasia. Cochrane Database Syst Rev 2012;(8):Cd000402.

  90. Grady D, Gebretsadik T, Kerlikowske K, Ernster V, Petitti D. Hormone replacement therapy and endometrial cancer risk: a meta-analysis. Obstet Gynecol 1995;85(2):304–13.

  91. Persson I, Weiderpass E, Bergkvist L, Bergström R, Schairer C. Risks of breast and endometrial cancer after estrogen and estrogen-progestin replacement. Cancer Causes Control 1999;10(4):253–60.

  92. Cohen I. Endometrial pathologies associated with postmenopausal tamoxifen treatment. Gynecol Oncol 2004;94(2):256–66.

  93. Fisher B, Costantino JP, Redmond CK, Fisher ER, Wickerham DL, Cronin WM. Endometrial cancer in tamoxifen-treated breast cancer patients: findings from the National Surgical Adjuvant Breast and Bowel Project (NSABP) B-14. J Natl Cancer Inst 1994;86(7):527–37.

  94. Neri F, Maggino T. Surveillance of endometrial pathologies, especially for endometrial cancer, of breast cancer patients under tamoxifen treatment. Eur J Gynaecol Oncol 2009;30(4):357–60.

  95. Fader AN, Arriba LN, Frasure HE, von Gruenigen VE. Endometrial cancer and obesity: epidemiology, biomarkers, prevention and survivorship. Gynecol Oncol 2009;114(1):121–7.

  96. Kaaks R, Lukanova A, Kurzer MS. Obesity, endogenous hormones, and endometrial cancer risk: a synthetic review. Cancer Epidemiol Biomarkers Prev 2002;11(12):1531–43.

  97. Tingthanatikul Y, Choktanasiri W, Rochanawutanon M, Weerakeit S. Prevalence and clinical predictors of endometrial hyperplasiain anovulatory women presenting with amenorrhea. Gynecol Endocrinol 2006;22(2):101–5.

  98. Zanagnolo V, Pasinetti B, Sartori E. Clinical review of 63 cases of sex cord stromal tumors. Eur J Gynaecol Oncol 2004;25(4):431–8.

  99. Chittenden BG, Fullerton G, Maheshwari A, Bhattacharya S. Polycystic ovary syndrome and the risk of gynaecological cancer: a systematic review. Reproductive biomedicine online 2009;19(3):398–405.

  100. Fearnley EJ, Marquart L, Spurdle AB, Weinstein P, Webb PM, Australian Ovarian Cancer Study Group and Australian National Endometrial Cancer Study Group. Polycystic ovary syndrome increases the risk of endometrial cancer in women aged less than 50 years: an Australian case-control study. Cancer Causes Control 2010;21(12):2303–8.

  101. Buchanan DD, Rosty C, Clendenning M, Spurdle AB, Win AK. Clinical problems of colorectal cancer and endometrial cancer cases with unknown cause of tumor mismatch repair deficiency (suspected Lynch syndrome). The application of clinical genetics 2014;7:183–93.

  102. Mork ME, Rodriguez A, Taggart MW, Rodriguez-Bigas MA, Lynch PM, Bannon SA, et al. Identification of MSH2 inversion of exons 1–7 in clinical evaluation of families with suspected Lynch syndrome. Fam Cancer 2017;16(3):357–61.

  103. Linkov F, Edwards R, Balk J, Yurkovetsky Z, Stadterman B, Lokshin A, et al. Endometrial hyperplasia, endometrial cancer and prevention: gaps in existing research of modifiable risk factors. Eur J Cancer 2008;44(12):1632–44.

  104. Bachmann LM, ter Riet G, Clark TJ, Gupta JK, Khan KS. Probability analysis for diagnosis of endometrial hyperplasia and cancer in postmenopausal bleeding: an approach for a rational diagnostic workup. Acta Obstet Gynecol Scand 2003;82(6):564–9.

  105. Vakiani M, Vavilis D, Agorastos T, Stamatopoulos P, Assimaki A, Bontis J. Histopathological findings of the endometrium in patients with dysfunctional uterine bleeding. Clin Exp Obstet Gynecol 1996;23(4):236–9.

  106. Gull B, Karlsson B, Milsom I, Granberg S. Can ultrasound replace dilation and curettage? A longitudinal evaluation of postmenopausal bleeding and transvaginal sonographic measurement of the endometrium as predictors of endometrial cancer. Am J Obstet Gynecol 2003;188(2):401–8.

  107. Committee on Gynecologic Practice, Society of Gynecologic Oncology,. The American College of Obstetricians and Gynecologists Committee Opinion no. 631. Endometrial intraepithelial neoplasia. Obstet Gynecol 2015;125(5):1272–8.

  108. Gallos ID, Shehmar M, Thangaratinam S, Papapostolou TK, Coomarasamy A, Gupta JK. Oral progestogens vs levonorgestrel-releasing intrauterine system for endometrial hyperplasia: a systematic review and metaanalysis. Am J Obstet Gynecol 2010;203(6):547.e1–10.

  109. Varma R, Soneja H, Bhatia K, Ganesan R, Rollason T, Clark TJ, et al. The effectiveness of a levonorgestrel-releasing intrauterine system (LNG-IUS) in the treatment of endometrial hyperplasia--a long-term follow-up study. Eur J Obstet Gynecol Reprod Biol 2008;139(2):169–75.

  110. Wildemeersch D, Janssens D, Pylyser K, De Wever N, Verbeeck G, Dhont M, et al. Management of patients with non-atypical and atypical endometrial hyperplasia with a levonorgestrel-releasing intrauterine system: long-term follow-up. Maturitas 2007;57(2):210–3.

  111. Nilsson CG, Haukkamaa M, Vierola H, Luukkainen T. Tissue concentrations of levonorgestrel in women using a levonorgestrel-releasing IUD. Clin Endocrinol (Oxf) 1982;17(6):529–36.

  112. Ørbo A, Arnes M, Vereide AB, Straume B. Relapse risk of endometrial hyperplasia after treatment with the levonorgestrel-impregnated intrauterine system or oral progestogens. BJOG 2016;123(9):1512–9.

  113. Perino A, Quartararo P, Catinella E, Genova G, Cittadini E. Treatment of endometrial hyperplasia with levonorgestrel releasing intrauterine devices. Acta Eur Fertil 1987;18(2):137–40.

  114. Scarselli G, Tantini C, Colafranceschi M, Taddei GL, Bargelli G, Venturini N, et al. Levo-norgestrel-nova-T and precancerous lesions of the endometrium. Eur J Gynaecol Oncol 1988;9(4):284–6.

  115. Ferenczy A, Gelfand M. The biologic significance of cytologic atypia in progestogen-treated endometrial hyperplasia. Am J Obstet Gynecol 1989;160(1):126–31.

  116. Randall TC, Kurman RJ. Progestin treatment of atypical hyperplasia and well-differentiated carcinoma of the endometrium in women under age 40. Obstet Gynecol 1997;90(3):434–40.

  117. Baker WD, Pierce SR, Mills AM, Gehrig PA, Duska LR. Nonoperative management of atypical endometrial hyperplasia and grade 1 endometrial cancer with the levonorgestrel intrauterine device in medically ill post-menopausal women. Gynecol Oncol 2017;146(1):34–8.

  118. Gallos ID, Ganesan R, Gupta JK. Prediction of regression and relapse of endometrial hyperplasia with conservative therapy. Obstet Gynecol 2013;121(6):1165–71.

  119. Gallos ID, Krishan P, Shehmar M, Ganesan R, Gupta JK. LNG-IUS versus oral progestogen treatment for endometrial hyperplasia: a long-term comparative cohort study. Hum Reprod 2013;28(11):2966–71.

  120. Sletten ET, Arnes M, Lysa LM, Moe BT, Straume B, Orbo A. Prediction of Relapse After Therapy Withdrawal in Women with Endometrial Hyperplasia: A Long-term Follow-up Study. Anticancer Res 2017;37(5):2529–36.

  121. Anastasiadis PG, Koutlaki NG, Skaphida PG, Galazios GC, Tsikouras PN, Liberis VA. Endometrial polyps: prevalence, detection, and malignant potential in women with abnormal uterine bleeding. Eur J Gynaecol Oncol 2000;21(2):180–3.

  122. Lieng M, Qvigstad E, Sandvik L, Jørgensen H, Langebrekke A, Istre O. Hysteroscopic resection of symptomatic and asymptomatic endometrial polyps. J Minim Invasive Gynecol 2007;14(2):189–94.

  123. Erickson BK, Conner MG, Landen CN, Jr. The role of the fallopian tube in the origin of ovarian cancer. Am J Obstet Gynecol 2013;209(5):409–14.

  124. Kuhn E, Kurman RJ, Vang R, Sehdev AS, Han G, Soslow R, et al. TP53 mutations in serous tubal intraepithelial carcinoma and concurrent pelvic high-grade serous carcinoma--evidence supporting the clonal relationship of the two lesions. J Pathol 2012;226(3):421–6.

  125. Sieh W, Salvador S, McGuire V, Weber RP, Terry KL, Rossing MA, et al. Tubal ligation and risk of ovarian cancer subtypes: a pooled analysis of case-control studies. Int J Epidemiol 2013;42(2):579–89.

  126. Larsen IK, red. Cancer in Norway 2013: cancer incidence, mortality, survival and prevalence in Norway. Oslo: Cancer Registry of Norway; 2015. Tilgjengelig fra: https://www.kreftregisteret.no/globalassets/cancer-in-norway/2013/cin_2013.pdf 

  127. Nakamura K, Banno K, Yanokura M, Iida M, Adachi M, Masuda K, et al. Features of ovarian cancer in Lynch syndrome (Review). Mol Clin Oncol 2014;2(6):909–16.

  128. Fathalla MF. Incessant ovulation--a factor in ovarian neoplasia? Lancet 1971;2(7716):163-.

  129. Purdie DM, Bain CJ, Siskind V, Webb PM, Green AC. Ovulation and risk of epithelial ovarian cancer. Int J Cancer 2003;104(2):228–32.

  130. Collaborative Group on Epidemiological Studies of Ovarian Cancer. Ovarian cancer and body size: individual participant meta-analysis including 25,157 women with ovarian cancer from 47 epidemiological studies. PLoS Med 2012;9(4):e1001200.

  131. Hunn J, Rodriguez GC. Ovarian cancer: etiology, risk factors, and epidemiology. Clin Obstet Gynecol 2012;55(1):3–23.

  132. Collaborative Group on Epidemiological Studies of Ovarian Cancer, Beral V, Doll R, Hermon C, Peto R, Reeves G. Ovarian cancer and oral contraceptives: collaborative reanalysis of data from 45 epidemiological studies including 23,257 women with ovarian cancer and 87,303 controls. Lancet 2008;371(9609):303–14.

  133. Brinton LA, James VL, Sherman ME. Epidemiology of Gynecologic Cancers. I: Barakat RR, Markman M, Randall ME, red. Principles and Practice of Gynecologic Oncology. 5. utg. Baltimore: Lippincott Williams & Wilkins; 2009. s. 1–30.

  134. Trabert B, Ness RB, Lo-Ciganic W-H, Murphy MA, Goode EL, Poole EM, et al. Aspirin, nonaspirin nonsteroidal anti-inflammatory drug, and acetaminophen use and risk of invasive epithelial ovarian cancer: a pooled analysis in the Ovarian Cancer Association Consortium. J Natl Cancer Inst 2014;106(2):djt431-djt.

  135. Paulsen T, Kærn J, Tropé C. Improved 5-year disease-free survival for FIGO stage I epithelial ovarian cancer patients without tumor rupture during surgery. Gynecol Oncol 2011;122(1):83–8.

  136. Vergote I, De Brabanter J, Fyles A, Bertelsen K, Einhorn N, Sevelda P, et al. Prognostic importance of degree of differentiation and cyst rupture in stage I invasive epithelial ovarian carcinoma. Lancet 2001;357(9251):176–82.

  137. Winter WE, 3rd, Maxwell GL, Tian C, Carlson JW, Ozols RF, Rose PG, et al. Prognostic factors for stage III epithelial ovarian cancer: a Gynecologic Oncology Group Study. J Clin Oncol 2007;25(24):3621–7.

  138. Harrison ML, Jameson C, Gore ME. Mucinous ovarian cancer. Int J Gynecol Cancer 2008;18(2):209–14.

  139. Itamochi H, Kigawa J, Terakawa N. Mechanisms of chemoresistance and poor prognosis in ovarian clear cell carcinoma. Cancer Sci 2008;99(4):653–8.

  140. Makar AP, Kristensen GB, Børmer OP, Trope CG. Serum CA 125 level allows early identification of nonresponders during induction chemotherapy. Gynecol Oncol 1993;49(1):73–9.

  141. Modan B, Hartge P, Hirsh-Yechezkel G, Chetrit A, Lubin F, Beller U, et al. Parity, oral contraceptives, and the risk of ovarian cancer among carriers and noncarriers of a BRCA1 or BRCA2 mutation. N Engl J Med 2001;345(4):235–40.

  142. Paulsen T, Kærn J, Kjærheim K, Tropé C, Tretli S. Symptoms and referral of women with epithelial ovarian tumors. Int J Gynaecol Obstet 2005;88(1):31–7.

  143. Goff BA, Mandel LS, Drescher CW, Urban N, Gough S, Schurman KM, et al. Development of an ovarian cancer symptom index: possibilities for earlier detection. Cancer 2007;109(2):221–7.

  144. Buamah PK, Rake MO, Drake SR, Skillen AW. Serum CA 12–5 concentrations and CA 12–5/CEA ratios in patients with epithelial ovarian cancer. J Surg Oncol 1990;44(2):97–9.

  145. Sørensen SS, Mosgaard BJ. Combination of cancer antigen 125 and carcinoembryonic antigen can improve ovarian cancer diagnosis. Dan Med Bull 2011;58(11):A4331-A.

  146. Yedema CA, Kenemans P, Wobbes T, Thomas CM, Bon GG, Mulder C, et al. Use of serum tumor markers in the differential diagnosis between ovarian and colorectal adenocarcinomas. Tumour Biol 1992;13(1–2):18–26.

  147. Tingulstad S, Hagen B, Skjeldestad FE, Halvorsen T, Nustad K, Onsrud M. The risk-of-malignancy index to evaluate potential ovarian cancers in local hospitals. Obstet Gynecol 1999;93(3):448–52.

  148. Domchek SM, Friebel TM, Singer CF, Evans DG, Lynch HT, Isaacs C, et al. Association of risk-reducing surgery in BRCA1 or BRCA2 mutation carriers with cancer risk and mortality. JAMA 2010;304(9):967–75.

  149. Gaba F, Piek J, Menon U, Manchanda R. Risk-reducing early salpingectomy and delayed oophorectomy as a two-staged alternative for primary prevention of ovarian cancer in women at increased risk: a commentary. BJOG 2019;126(7):831–9.

  150. Decloedt J, Vergote I. Laparoscopy in gynaecologic oncology: a review. Crit Rev Oncol Hematol 1999;31(1):15–26.

  151. Tropé CG, Davidson B, Dørum A, Kærn J, Kristensen GB, Paulsen T, et al. Epithelial ovarian cancer. I: Peltecu GC, Tropé CG, red. Gynecol Oncol. Bucharest: The Publishing House of the Romanian Academy; 2010. s. 357–444.

  152. Vernooij F, Heintz P, Witteveen E, van der Graaf Y. The outcomes of ovarian cancer treatment are better when provided by gynecologic oncologists and in specialized hospitals: a systematic review. Gynecol Oncol 2007;105(3):801–12.

  153. Giede KC, Kieser K, Dodge J, Rosen B. Who should operate on patients with ovarian cancer? An evidence-based review. Gynecol Oncol 2005;99(2):447–61.

  154. Paulsen T, Kjaerheim K, Kaern J, Tretli S, Trope C. Improved short-term survival for advanced ovarian, tubal, and peritoneal cancer patients operated at teaching hospitals. Int J Gynecol Cancer 2006;16 Suppl 1:11–7.

  155. Bristow RE, Santillan A, Diaz-Montes TP, Gardner GJ, Giuntoli RL, 2nd, Meisner BC, et al. Centralization of care for patients with advanced-stage ovarian cancer: a cost-effectiveness analysis. Cancer 2007;109(8):1513–22.

  156. Chi DS, Eisenhauer EL, Lang J, Huh J, Haddad L, Abu-Rustum NR, et al. What is the optimal goal of primary cytoreductive surgery for bulky stage IIIC epithelial ovarian carcinoma (EOC)? Gynecol Oncol 2006;103(2):559–64.

  157. Bristow RE, Chi DS. Platinum-based neoadjuvant chemotherapy and interval surgical cytoreduction for advanced ovarian cancer: a meta-analysis. Gynecol Oncol 2006;103(3):1070–6.

  158. Gill SE, McGree ME, Weaver AL, Cliby WA, Langstraat CL. Optimizing the treatment of ovarian cancer: Neoadjuvant chemotherapy and interval debulking versus primary debulking surgery for epithelial ovarian cancers likely to have suboptimal resection. Gynecol Oncol 2017;144(2):266–73.

  159. Kehoe S, Hook J, Nankivell M, Jayson GC, Kitchener H, Lopes T, et al. Primary chemotherapy versus primary surgery for newly diagnosed advanced ovarian cancer (CHORUS): an open-label, randomised, controlled, non-inferiority trial. Lancet 2015;386(9990):249–57.

  160. Kessous R, Laskov I, Abitbol J, Bitharas J, Yasmeen A, Salvador S, et al. Clinical outcome of neoadjuvant chemotherapy for advanced ovarian cancer. Gynecol Oncol 2017;144(3):474–9.

  161. Marchetti C, Kristeleit R, McCormack M, Mould T, Olaitan A, Widschwendter M, et al. Outcome of patients with advanced ovarian cancer who do not undergo debulking surgery: A single institution retrospective review. Gynecol Oncol 2017;144(1):57–60.

  162. Phillips A, Sundar S, Singh K, Nevin J, Elattar A, Kehoe S, et al. Complete cytoreduction after five or more cycles of neo-adjuvant chemotherapy confers a survival benefit in advanced ovarian cancer. Eur J Surg Oncol 2018;44(6):760–5.

  163. Vergote I, Trope CG, Amant F, Kristensen GB, Ehlen T, Johnson N, et al. Neoadjuvant chemotherapy or primary surgery in stage IIIC or IV ovarian cancer. N Engl J Med 2010;363(10):943–53.

  164. Jacquet P, Sugarbaker PH. Clinical research methodologies in diagnosis and staging of patients with peritoneal carcinomatosis. Cancer Treat Res 1996;82:359–74.

  165. Harter P, Sehouli J, Lorusso D, Reuss A, Vergote I, Marth C, et al. LION: Lymphadenectomy in ovarian neoplasms—A prospective randomized AGO study group led gynecologic cancer intergroup trial. J Clin Oncol 2017;35(15_suppl):5500.

  166. Camara O, Sehouli J. Controversies in the management of ovarian cancer--pros and cons for lymph node dissection in ovarian cancer. Anticancer Res 2009;29(7):2837–43.

  167. Heitz F, Harter P, Ataseven B, Heikaus S, Schneider S, Prader S, et al. Stage- and Histologic Subtype-Dependent Frequency of Lymph Node Metastases in Patients with Epithelial Ovarian Cancer Undergoing Systematic Pelvic and Paraaortic Lymphadenectomy. Ann Surg Oncol 2018;25(7):2053–9.

  168. Wethington SL, Park KJ, Soslow RA, Kauff ND, Brown CL, Dao F, et al. Clinical outcome of isolated serous tubal intraepithelial carcinomas (STIC). Int J Gynecol Cancer 2013;23(9):1603–11.

  169. Weinberger V, Bednarikova M, Cibula D, Zikan M. Serous tubal intraepithelial carcinoma (STIC) – clinical impact and management. Expert Rev Anticancer Ther 2016;16(12):1311–21.

  170. Powell CB, Chen LM, McLennan J, Crawford B, Zaloudek C, Rabban JT, et al. Risk-reducing salpingo-oophorectomy (RRSO) in BRCA mutation carriers: experience with a consecutive series of 111 patients using a standardized surgical-pathological protocol. Int J Gynecol Cancer 2011;21(5):846–51.

  171. Hess V, A'Hern R, Nasiri N, King DM, Blake PR, Barton DPJ, et al. Mucinous epithelial ovarian cancer: a separate entity requiring specific treatment. J Clin Oncol 2004;22(6):1040–4.

  172. Bentivegna E, Morice P, Uzan C, Gouy S. Fertility-sparing surgery in epithelial ovarian cancer. Future Oncol 2016;12(3):389–98.

  173. Gouy S, Saidani M, Maulard A, Faron M, Bach-Hamba S, Bentivegna E, et al. Staging surgery in early-stage ovarian mucinous tumors according to expansile and infiltrative types. Gynecol Oncol Rep 2017;22:21–5.

  174. Lago V, Minig L, Fotopoulou C. Incidence of Lymph Node Metastases in Apparent Early-Stage Low-Grade Epithelial Ovarian Cancer: A Comprehensive Review. Int J Gynecol Cancer 2016;26(8):1407–14.

  175. Muyldermans K, Moerman P, Amant F, Leunen K, Neven P, Vergote I. Primary invasive mucinous ovarian carcinoma of the intestinal type: importance of the expansile versus infiltrative type in predicting recurrence and lymph node metastases. Eur J Cancer 2013;49(7):1600–8.

  176. Minig L, Heitz F, Cibula D, Bakkum-Gamez JN, Germanova A, Dowdy SC, et al. Patterns of Lymph Node Metastases in Apparent Stage I Low-Grade Epithelial Ovarian Cancer: A Multicenter Study. Ann Surg Oncol 2017;24(9):2720–6.

  177. Bachmann C, Bachmann R, Brucker SY, Staebler A, Fend F, Grischke EM, et al. Role of Pelvic and Para-aortic Lymph Node Metastases in Optimally Cytoreduced Advanced Ovarian Cancer. Anticancer Res 2015;35(6):3479–84.

  178. Panici PB, Maggioni A, Hacker N, Landoni F, Ackermann S, Campagnutta E, et al. Systematic aortic and pelvic lymphadenectomy versus resection of bulky nodes only in optimally debulked advanced ovarian cancer: a randomized clinical trial. J Natl Cancer Inst 2005;97(8):560–6.

  179. Szczesny W, Langseth H, Myklebust TÅ, Kaern J, Tropé C, Paulsen T. Survival after secondary cytoreductive surgery and chemotherapy compared with chemotherapy alone for first recurrence in patients with platinum-sensitive epithelial ovarian cancer and no residuals after primary treatment. A registry-based study. Acta Obstet Gynecol Scand 2018;May 22 [Epub ahead of print].

  180. Colombo N, Sessa C, du Bois A, Ledermann J, McCluggage WG, McNeish I, et al. ESMO-ESGO consensus conference recommendations on ovarian cancer: pathology and molecular biology, early and advanced stages, borderline tumours and recurrent disease†. Ann Oncol 2019;30(5):672–705.

  181. Hogen L, Brar H, Covens A, Bassiouny D, Bernardini MQ, Gien LT, et al. Is adjuvant chemotherapy beneficial for surgical stage I ovarian clear cell carcinoma? Gynecol Oncol 2017;147(1):54–60.

  182. Chan JK, Tian C, Teoh D, Monk BJ, Herzog T, Kapp DS, et al. Survival after recurrence in early-stage high-risk epithelial ovarian cancer: a Gynecologic Oncology Group study. Gynecol Oncol 2010;116(3):307–11.

  183. Colombo N, Sessa C, Bois Ad, Ledermann J, McCluggage WG, McNeish I, et al. ESMO–ESGO consensus conference recommendations on ovarian cancer: pathology and molecular biology, early and advanced stages, borderline tumours and recurrent disease. Int J Gynecol Cancer 2019;29(4):728–60.

  184. Trimbos JB, Parmar M, Vergote I, Guthrie D, Bolis G, Colombo N, et al. International Collaborative Ovarian Neoplasm trial 1 and Adjuvant ChemoTherapy In Ovarian Neoplasm trial: two parallel randomized phase III trials of adjuvant chemotherapy in patients with early-stage ovarian carcinoma. J Natl Cancer Inst 2003;95(2):105–12.

  185. Shi Q, Sobrero AF, Shields AF, Yoshino T, Paul J, Taieb J, et al. Prospective pooled analysis of six phase III trials investigating duration of adjuvant (adjuv) oxaliplatin-based therapy (3 vs 6 months) for patients (pts) with stage III colon cancer (CC): The IDEA (International Duration Evaluation of Adjuvant chemotherapy) collaboration. J Clin Oncol 2017;35(18_suppl):LBA1-LBA.

  186. Gore ME, Hackshaw A, Brady WE, Penson RT, Zaino RJ, McCluggage WG, et al. Multicentre trial of carboplatin/paclitaxel versus oxaliplatin/capecitabine, each with/without bevacizumab, as first line chemotherapy for patients with mucinous epithelial ovarian cancer (mEOC). J Clin Oncol 2015;33(SUPPL.):abstract 5528.

  187. Mahner S, Eulenburg C, Staehle A, Wegscheider K, Reuss A, Pujade-Lauraine E, et al. Prognostic impact of the time interval between surgery and chemotherapy in advanced ovarian cancer: analysis of prospective randomised phase III trials. Eur J Cancer 2013;49(1):142–9.

  188. Ozols RF, Bundy BN, Greer BE, Fowler JM, Clarke-Pearson D, Burger RA, et al. Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: a Gynecologic Oncology Group study. J Clin Oncol 2003;21(17):3194–200.

  189. Perren TJ, Swart AM, Pfisterer J, Ledermann JA, Pujade-Lauraine E, Kristensen G, et al. A phase 3 trial of bevacizumab in ovarian cancer. N Engl J Med 2011;365(26):2484–96.

  190. Pujade-Lauraine E, Hilpert F, Weber B, Reuss A, Poveda A, Kristensen G, et al. Bevacizumab combined with chemotherapy for platinum-resistant recurrent ovarian cancer: The AURELIA open-label randomized phase III trial. J Clin Oncol 2014;32(13):1302–8.

  191. Stockler MR, Hilpert F, Friedlander M, King MT, Wenzel L, Lee CK, et al. Patient-reported outcome results from the open-label phase III AURELIA trial evaluating bevacizumab-containing therapy for platinum-resistant ovarian cancer. J Clin Oncol 2014;32(13):1309–16.

  192. Perren TJ. Mucinous epithelial ovarian carcinoma. Ann Oncol 2016;27(suppl_1):i53-i7.

  193. Vasey PA, Atkinson R, Coleman R, Crawford M, Cruickshank M, Eggleton P, et al. Docetaxel-carboplatin as first line chemotherapy for epithelial ovarian cancer. Br J Cancer 2001;84(2):170–8.

  194. Pignata S, Scambia G, Ferrandina G, Savarese A, Sorio R, Breda E, et al. Carboplatin plus paclitaxel versus carboplatin plus pegylated liposomal doxorubicin as first-line treatment for patients with ovarian cancer: the MITO-2 randomized phase III trial. J Clin Oncol 2011;29(27):3628–35.

  195. von Gruenigen VE, Huang HQ, Beumer JH, Lankes HA, Tew W, Herzog T, et al. Chemotherapy completion in elderly women with ovarian, primary peritoneal or fallopian tube cancer – An NRG oncology/Gynecologic Oncology Group study. Gynecol Oncol 2017;144(3):459–67.

  196. Oguri T, Shimokata T, Ito I, Yasuda Y, Sassa N, Nishiyama M, et al. Extension of the Calvert formula to patients with severe renal insufficiency. Cancer Chemother Pharmacol 2015;76(1):53–9.

  197. Hinde S, Epstein D, Cook A, Embleton A, Perren T, Sculpher M. The Cost-Effectiveness of Bevacizumab in Advanced Ovarian Cancer Using Evidence from the ICON7 Trial. Value Health 2016;19(4):431–9.

  198. Essel KG, Moore KN. Niraparib for the treatment of ovarian cancer. Expert Rev Anticancer Ther 2018;18(8):727–33.

  199. Ledermann J, Harter P, Gourley C, Friedlander M, Vergote I, Rustin G, et al. Olaparib maintenance therapy in platinum-sensitive relapsed ovarian cancer. N Engl J Med 2012;366(15):1382–92.

  200. Ledermann J, Harter P, Gourley C, Friedlander M, Vergote I, Rustin G, et al. Olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer: a preplanned retrospective analysis of outcomes by BRCA status in a randomised phase 2 trial. Lancet Oncol 2014;15(8):852–61.

  201. Gershenson DM, Bodurka DC, Coleman RL, Lu KH, Malpica A, Sun CC. Hormonal Maintenance Therapy for Women With Low-Grade Serous Cancer of the Ovary or Peritoneum. J Clin Oncol 2017;35(10):1103–11.

  202. Muallem MZ, Gasimli K, Richter R, Almuheimid J, Nasser S, Braicu EI, et al. AGO Score As a Predictor of Surgical Outcome at Secondary Cytoreduction in Patients with Ovarian Cancer. Anticancer Res 2015;35(6):3423–9.

  203. Champer M, Huang Y, Hou JY, Tergas AI, Burke WM, Hillyer GC, et al. Adherence to treatment recommendations and outcomes for women with ovarian cancer at first recurrence. Gynecol Oncol 2018;148(1):19–27.

  204. Gore ME, Fryatt I, Wiltshaw E, Dawson T. Treatment of relapsed carcinoma of the ovary with cisplatin or carboplatin following initial treatment with these compounds. Gynecol Oncol 1990;36(2):207–11.

  205. Mirza MR, Monk BJ, Herrstedt J, Oza AM, Mahner S, Redondo A, et al. Niraparib Maintenance Therapy in Platinum-Sensitive, Recurrent Ovarian Cancer. N Engl J Med 2016;375(22):2154–64.

  206. Blackledge G, Lawton F, Redman C, Kelly K. Response of patients in phase II studies of chemotherapy in ovarian cancer: implications for patient treatment and the design of phase II trials. Br J Cancer 1989;59(4):650–3.

  207. Parmar MKB, Ledermann JA, Colombo N, du Bois A, Delaloye JF, Kristensen GB, et al. Paclitaxel plus platinum-based chemotherapy versus conventional platinum-based chemotherapy in women with relapsed ovarian cancer: the ICON4/AGO-OVAR-2.2 trial. Lancet 2003;361(9375):2099–106.

  208. Raja FA, Counsell N, Colombo N, Pfisterer J, du Bois A, Parmar MK, et al. Platinum versus platinum-combination chemotherapy in platinum-sensitive recurrent ovarian cancer: a meta-analysis using individual patient data. Ann Oncol 2013;24(12):3028–34.

  209. Oza AM, Cibula D, Benzaquen AO, Poole C, Mathijssen RHJ, Sonke GS, et al. Olaparib combined with chemotherapy for recurrent platinum-sensitive ovarian cancer: a randomised phase 2 trial. Lancet Oncol 2015;16(1):87–97.

  210. Monk BJ, Herzog TJ, Tewari KS. Evolution of Chemosensitivity and Resistance Assays as Predictors of Clinical Outcomes in Epithelial Ovarian Cancer Patients. Curr Pharm Des 2016;22(30):4717–28.

  211. Lindemann K, Gibbs E, Åvall-Lundqvist E, dePont Christensen R, Woie K, Kalling M, et al. Chemotherapy vs tamoxifen in platinum-resistant ovarian cancer: a phase III, randomised, multicentre trial (Ovaresist). Br J Cancer 2017;116(4):455–63.

  212. Harter P, du Bois A, Hahmann M, Hasenburg A, Burges A, Loibl S, et al. Surgery in recurrent ovarian cancer: the Arbeitsgemeinschaft Gynaekologische Onkologie (AGO) DESKTOP OVAR trial. Ann Surg Oncol 2006;13(12):1702–10.

  213. Oksefjell H, Sandstad B, Trope C. The role of secondary cytoreduction in the management of the first relapse in epithelial ovarian cancer. Ann Oncol 2009;20(2):286–93.

  214. Bristow RE, Puri I, Chi DS. Cytoreductive surgery for recurrent ovarian cancer: a meta-analysis. Gynecol Oncol 2009;112(1):265–74.

  215. Rustin GJ, van der Burg ME, Griffin CL, Guthrie D, Lamont A, Jayson GC, et al. Early versus delayed treatment of relapsed ovarian cancer (MRC OV05/EORTC 55955): a randomised trial. Lancet 2010;376(9747):1155–63.

  216. Rustin GJ, Quinn M, Thigpen T, du Bois A, Pujade-Lauraine E, Jakobsen A, et al. Re: New guidelines to evaluate the response to treatment in solid tumors (ovarian cancer). J Natl Cancer Inst 2004;96(6):487–8.

  217. Liavaag AH, Dørum A, Fosså SD, Trope C, Dahl AA. Controlled study of fatigue, quality of life, and somatic and mental morbidity in epithelial ovarian cancer survivors: how lucky are the lucky ones? J Clin Oncol 2007;25(15):2049–56.

  218. Friebel TM, Domchek SM, Rebbeck TR. Modifiers of cancer risk in BRCA1 and BRCA2 mutation carriers: systematic review and meta-analysis. J Natl Cancer Inst 2014;106(6):dju091-dju.

  219. Antoniou A, Pharoah PD, Narod S, Risch HA, Eyfjord JE, Hopper JL, et al. Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case Series unselected for family history: a combined analysis of 22 studies. Am J Hum Genet 2003;72(5):1117–30.

  220. Kuchenbaecker KB, Hopper JL, Barnes DR, Phillips K-A, Mooij TM, Roos-Blom M-J, et al. Risks of Breast, Ovarian, and Contralateral Breast Cancer for BRCA1 and BRCA2 Mutation Carriers. JAMA 2017;317(23):2402–16.

  221. Lakhani SR, Manek S, Penault-Llorca F, Flanagan A, Arnout L, Merrett S, et al. Pathology of ovarian cancers in BRCA1 and BRCA2 carriers. Clin Cancer Res 2004;10(7):2473–81.

  222. Piver MS. Hereditary ovarian cancer. Lessons from the first twenty years of the Gilda Radner Familial Ovarian Cancer Registry. Gynecol Oncol 2002;85(1):9–17.

  223. Crijnen TEM, Janssen-Heijnen MLG, Gelderblom H, Morreau J, Nooij MA, Kenter GG, et al. Survival of patients with ovarian cancer due to a mismatch repair defect. Fam Cancer 2005;4(4):301–5.

  224. Watson P, Bützow R, Lynch HT, Mecklin JP, Järvinen HJ, Vasen HF, et al. The clinical features of ovarian cancer in hereditary nonpolyposis colorectal cancer. Gynecol Oncol 2001;82(2):223–8.

  225. Grindedal EM, Renkonen-Sinisalo L, Vasen H, Evans G, Sala P, Blanco I, et al. Survival in women with MMR mutations and ovarian cancer: a multicentre study in Lynch syndrome kindreds. J Med Genet 2010;47(2):99–102.

  226. Kurman RJ, Shih Ie M. The origin and pathogenesis of epithelial ovarian cancer: a proposed unifying theory. Am J Surg Pathol 2010;34(3):433–43.

  227. Toss A, Tomasello C, Razzaboni E, Contu G, Grandi G, Cagnacci A, et al. Hereditary ovarian cancer: not only BRCA 1 and 2 genes. Biomed Res Int 2015;2015:341723.

  228. Nasjonalt handlingsprogram med retningslinjer for diagnostikk, behandling og oppfølging av pasienter med brystkreft. Oslo: Helsedirektoratet; 2019. IS-2831. Tilgjengelig fra: https://www.helsedirektoratet.no/retningslinjer/brystkreft-handlingsprogram 

  229. Hogg R, Friedlander M. Biology of epithelial ovarian cancer: implications for screening women at high genetic risk. J Clin Oncol 2004;22(7):1315–27.

  230. Dørum A, Heimdal K, Løvslett K, Kristensen G, Hansen LJ, Sandvei R, et al. Prospectively detected cancer in familial breast/ovarian cancer screening. Acta Obstet Gynecol Scand 1999;78(10):906–11.

  231. Gaarenstroom KN, van der Hiel B, Tollenaar RAEM, Vink GR, Jansen FW, van Asperen CJ, et al. Efficacy of screening women at high risk of hereditary ovarian cancer: results of an 11-year cohort study. Int J Gynecol Cancer 2006;16 Suppl 1:54–9.

  232. Hermsen BBJ, Olivier RI, Verheijen RHM, van Beurden M, de Hullu JA, Massuger LF, et al. No efficacy of annual gynaecological screening in BRCA1/2 mutation carriers; an observational follow-up study. Br J Cancer 2007;96(9):1335–42.

  233. Guidelines for familial high-risk assessment breast and ovarian cancer. Fort Washington, PA: National Comprehencive Cancer Network; 2014.

  234. Kehoe SM, Kauff ND. Screening and prevention of hereditary gynecologic cancers. Semin Oncol 2007;34(5):406–10.

  235. Sharma A, Menon U. Screening for gynaecological cancers. Eur J Surg Oncol 2006;32(8):818–24.

  236. Tailor A, Bourne TH, Campbell S, Okokon E, Dew T, Collins WP. Results from an ultrasound-based familial ovarian cancer screening clinic: a 10-year observational study. Ultrasound Obstet Gynecol 2003;21(4):378–85.

  237. Kurman RJ, Shih Ie M. Molecular pathogenesis and extraovarian origin of epithelial ovarian cancer--shifting the paradigm. Hum Pathol 2011;42(7):918–31.

  238. Langmar Z, Nemeth M, Vlesko G, Kiraly M, Hornyak L, Bosze P. HE4--a novel promising serum marker in the diagnosis of ovarian carcinoma. Eur J Gynaecol Oncol 2011;32(6):605–10.

  239. Barakat R, Hensley ML, Bhaskaran D, Rastogi P, Korytowsky B, Boyd J, et al. Prophylactic Oophorectomy in Patients at Risk for Hereditary Ovarian Carcinoma. Gynecol Oncol 2002;84(3):482.

  240. Finch APM, Lubinski J, Møller P, Singer CF, Karlan B, Senter L, et al. Impact of oophorectomy on cancer incidence and mortality in women with a BRCA1 or BRCA2 mutation. J Clin Oncol 2014;32(15):1547–53.

  241. Rebbeck TR, Kauff ND, Domchek SM. Meta-analysis of risk reduction estimates associated with risk-reducing salpingo-oophorectomy in BRCA1 or BRCA2 mutation carriers. J Natl Cancer Inst 2009;101(2):80–7.

  242. Hartmann LC, Lindor NM. The Role of Risk-Reducing Surgery in Hereditary Breast and Ovarian Cancer. N Engl J Med 2016;374(5):454–68.

  243. Heemskerk-Gerritsen BAM, Seynaeve C, van Asperen CJ, Ausems MGEM, Collée JM, van Doorn HC, et al. Breast cancer risk after salpingo-oophorectomy in healthy BRCA1/2 mutation carriers: revisiting the evidence for risk reduction. J Natl Cancer Inst 2015;107(5):djv033.

  244. Dørum A, Tonstad S, Liavaag AH, Michelsen TM, Hildrum B, Dahl AA. Bilateral oophorectomy before 50 years of age is significantly associated with the metabolic syndrome and Framingham risk score: a controlled, population-based study (HUNT-2). Gynecol Oncol 2008;109(3):377–83.

  245. Lobo RA. Surgical menopause and cardiovascular risks. Menopause 2007;14(3 Pt 2):562–6.

  246. Madalinska JB, van Beurden M, Bleiker EM, Valdimarsdottir HB, Hollenstein J, Massuger LF, et al. The impact of hormone replacement therapy on menopausal symptoms in younger high-risk women after prophylactic salpingo-oophorectomy. J Clin Oncol 2006;24(22):3576–82.

  247. Kauff ND, Domchek SM, Friebel TM, Robson ME, Lee J, Garber JE, et al. Risk-reducing salpingo-oophorectomy for the prevention of BRCA1- and BRCA2-associated breast and gynecologic cancer: a multicenter, prospective study. J Clin Oncol 2008;26(8):1331–7.

  248. Evans DGR, Clayton R, Donnai P, Shenton A, Lalloo F. Risk-reducing surgery for ovarian cancer: outcomes in 300 surgeries suggest a low peritoneal primary risk. Eur J Hum Genet 2009;17(11):1381–5.

  249. Hanley GE, McAlpine JN, Kwon JS, Mitchell G. Opportunistic salpingectomy for ovarian cancer prevention. Gynecol Oncol Res Pract 2015;2:5.

  250. Moorman PG, Havrilesky LJ, Gierisch JM, Coeytaux RR, Lowery WJ, Peragallo Urrutia R, et al. Oral contraceptives and risk of ovarian cancer and breast cancer among high-risk women: a systematic review and meta-analysis. J Clin Oncol 2013;31(33):4188–98.

  251. Brohet RM, Goldgar DE, Easton DF, Antoniou AC, Andrieu N, Chang-Claude J, et al. Oral contraceptives and breast cancer risk in the international BRCA1/2 carrier cohort study: a report from EMBRACE, GENEPSO, GEO-HEBON, and the IBCCS Collaborating Group. J Clin Oncol 2007;25(25):3831–6.

  252. Iodice S, Barile M, Rotmensz N, Feroce I, Bonanni B, Radice P, et al. Oral contraceptive use and breast or ovarian cancer risk in BRCA1/2 carriers: a meta-analysis. Eur J Cancer 2010;46(12):2275–84.

  253. Pasanisi P, Hédelin G, Berrino J, Chang-Claude J, Hermann S, Steel M, et al. Oral contraceptive use and BRCA penetrance: a case-only study. Cancer Epidemiol Biomarkers Prev 2009;18(7):2107–13.

  254. Hankinson SE, Hunter DJ, Colditz GA, Willett WC, Stampfer MJ, Rosner B, et al. Tubal ligation, hysterectomy, and risk of ovarian cancer. A prospective study. JAMA 1993;270(23):2813–8.

  255. Domchek S, Kaunitz AM. Use of systemic hormone therapy in BRCA mutation carriers. Menopause 2016;23(9):1026–7.

  256. Peccatori F, Bonazzi C, Chiari S, Landoni F, Colombo N, Mangioni C. Surgical management of malignant ovarian germ-cell tumors: 10 years' experience of 129 patients. Obstet Gynecol 1995;86(3):367–72.

  257. Gershenson DM. Update on malignant ovarian germ cell tumors. Cancer 1993;71(4 Suppl):1581–90.

  258. Gershenson DM. Management of ovarian germ cell tumors. J Clin Oncol 2007;25(20):2938–43.

  259. Brewer M, Gershenson DM, Herzog CE, Mitchell MF, Silva EG, Wharton JT. Outcome and reproductive function after chemotherapy for ovarian dysgerminoma. J Clin Oncol 1999;17(9):2670–75.

  260. Berek JS, Hacker NF. Nonepitelial ovarian and fallopian tube cancers. I: Berek JS, Hacker NF, red. Practical Gynecologic Oncology. Philadelphia: Lippincott Williams & Wilkins; 2010. s. 509–36.

  261. Colombo N, Parma G, Zanagnolo V, Insinga A. Management of ovarian stromal cell tumors. J Clin Oncol 2007;25(20):2944–51.

  262. Williams S. I: Gershenson DM, McGuire WP, red. Ovarian Cancer: Controversies in Management. New York: Churchil Livingstone; 1998. s. 403–4.

  263. Abu-Rustum NR, Aghajanian C. Management of malignant germ cell tumors of the ovary. Semin Oncol 1998;25(2):235–42.

  264. Billmire D, Vinocur C, Rescorla F, Cushing B, London W, Schlatter M, et al. Outcome and staging evaluation in malignant germ cell tumors of the ovary in children and adolescents: an intergroup study. J Pediatr Surg 2004;39(3):424–9; discussion -9.

  265. Sehouli J, Drescher FS, Mustea A, Elling D, Friedmann W, Kuhn W, et al. Granulosa cell tumor of the ovary: 10 years follow-up data of 65 patients. Anticancer Res 2004;24(2c):1223–9.

  266. Ovarian cancer. Version 3.2014. Fort Washington, PA: National Comprehencive Cancer Network; 2014.

  267. Hauptmann S, Friedrich K, Redline R, Avril S. Ovarian borderline tumors in the 2014 WHO classification: evolving concepts and diagnostic criteria. Virchows Arch 2017;470(2):125–42.

  268. Prat J, FIGO Committee on Gynecologic Oncology. Staging classification for cancer of the ovary, fallopian tube, and peritoneum. Int J Gynaecol Obstet 2014;124(1):1–5.

  269. du Bois A, Ewald-Riegler N, Bois OD, Harter P. Borderline-tumoren des ovars – Eine systematische ubersicht. Geburtshilfe Frauenheilkd 2009;69(9):807–33.

  270. Lalwani N, Shanbhogue AKP, Vikram R, Nagar A, Jagirdar J, Prasad SR. Current update on borderline ovarian neoplasms. AJR Am J Roentgenol 2010;194(2):330–6.

  271. Lenhard MS, Mitterer S, Kümper C, Stieber P, Mayr D, Ditsch N, et al. Long-term follow-up after ovarian borderline tumor: relapse and survival in a large patient cohort. Eur J Obstet Gynecol Reprod Biol 2009;145(2):189–94.

  272. Silva EG, Gershenson DM, Malpica A, Deavers M. The recurrence and the overall survival rates of ovarian serous borderline neoplasms with noninvasive implants is time dependent. Am J Surg Pathol 2006;30(11):1367–71.

  273. Park JM, Kim MK. Hereditary risk evaluation for borderline ovarian tumors based on immunohistochemistry. J Menopausal Med 2014;20(1):14–20.

  274. Burger CW, Van De Swaluw A, Mooij TM, Van Leeuwen FE. Risk of borderline and invasive ovarian tumors after ovarian stimulation for in vitro fertilization in a large Dutch cohort after 15 years of follow-up. Gynecol Oncol 2009;1:S4-S5.

  275. Fortin A, Morice P, Thoury A, Camatte S, Dhainaut C, Madelenat P. Impact of infertility drugs after treatment of borderline ovarian tumors: results of a retrospective multicenter study. Fertil Steril 2007;87(3):591–6.

  276. Riman T, Dickman PW, Nilsson S, Correia N, Nordlinder H, Magnusson CM, et al. Risk factors for epithelial borderline ovarian tumors: results of a Swedish case-control study. Gynecol Oncol 2001;83(3):575–85.

  277. Bjørge T, Engeland A, Hansen S, Tropé CG. Prognosis of patients with ovarian cancer and borderline tumours diagnosed in Norway between 1954 and 1993. Int J Cancer 1998;75(5):663–70.

  278. du Bois A, Ewald-Riegler N, de Gregorio N, Reuss A, Mahner S, Fotopoulou C, et al. Borderline tumours of the ovary: A cohort study of the Arbeitsgmeinschaft Gynäkologische Onkologie (AGO) Study Group. Eur J Cancer 2013;49(8):1905–14.

  279. Seidman JD, Kurman RJ. Ovarian serous borderline tumors: a critical review of the literature with emphasis on prognostic indicators. Hum Pathol 2000;31(5):539–57.

  280. Paulsen T. Epithelial ovarian cancer: a clinical epidemiological approach on diagnosis and treatment [doktorgrad]. Oslo: University of Oslo; 2007. Series of dissertations submitted to the Faculty of Medicine, University of Oslo No.549. Tilgjengelig fra: https://www.duo.uio.no/handle/10852/28083 

  281. Ødegaard E, Staff AC, Langebrekke A, Engh V, Onsrud M. Surgery of borderline tumors of the ovary: retrospective comparison of short-term outcome after laparoscopy or laparotomy. Acta Obstet Gynecol Scand 2007;86(5):620–6.

  282. Cadron I, Leunen K, Van Gorp T, Amant F, Neven P, Vergote I. Management of borderline ovarian neoplasms. J Clin Oncol 2007;25(20):2928–37.

  283. Coumbos A, Sehouli J, Chekerov R, Schaedel D, Oskay-Oezcelik G, Lichtenegger W, et al. Clinical management of borderline tumours of the ovary: results of a multicentre survey of 323 clinics in Germany. Br J Cancer 2009;100(11):1731–8.

  284. Tinelli R, Tinelli A, Tinelli FG, Cicinelli E, Malvasi A. Conservative surgery for borderline ovarian tumors: a review. Gynecol Oncol 2006;100(1):185–91.

  285. Camatte S, Morice P, Thoury A, Fourchotte V, Pautier P, Lhomme C, et al. Impact of surgical staging in patients with macroscopic "stage I" ovarian borderline tumours: analysis of a continuous series of 101 cases. Eur J Cancer 2004;40(12):1842–9.

  286. Fadare O. Recent developments on the significance and pathogenesis of lymph node involvement in ovarian serous tumors of low malignant potential (borderline tumors). Int J Gynecol Cancer 2009;19(1):103–8.

  287. Kurman RJ, Seidman JD, Shih IM. Serous borderline tumours of the ovary. Histopathology 2005;47(3):310–5.

  288. McKenney JK, Balzer BL, Longacre TA. Lymph node involvement in ovarian serous tumors of low malignant potential (borderline tumors): pathology, prognosis, and proposed classification. Am J Surg Pathol 2006;30(5):614–24.

  289. Tropé C, Kærn J, Vergote IB, Kristensen G, Abeler V. Are borderline tumors of the ovary overtreated both surgically and systemically? A review of four prospective randomized trials including 253 patients with borderline tumors. Gynecol Oncol 1993;51(2):236–43.

  290. Longacre TA, McKenney JK, Tazelaar HD, Kempson RL, Hendrickson MR. Ovarian serous tumors of low malignant potential (borderline tumors): outcome-based study of 276 patients with long-term (> or =5-year) follow-up. Am J Surg Pathol 2005;29(6):707–23.

  291. Trillsch F, Mahner S, Vettorazzi E, Woelber L, Reuss A, Baumann K, et al. Surgical staging and prognosis in serous borderline ovarian tumours (BOT): a subanalysis of the AGO ROBOT study. Br J Cancer 2015;112(4):660–6.

  292. Harter P, Gershenson D, Lhomme C, Lecuru F, Ledermann J, Provencher DM, et al. Gynecologic Cancer InterGroup (GCIG) consensus review for ovarian tumors of low malignant potential (borderline ovarian tumors). Int J Gynecol Cancer 2014;24(9 Suppl 3):S5–8.

  293. Morice P, Camatte S, Wicart-Poque F, Atallah D, Rouzier R, Pautier P, et al. Results of conservative management of epithelial malignant and borderline ovarian tumours. Hum Reprod Update 2003;9(2):185–92.

  294. Fauvet R, Boccara J, Dufournet C, Poncelet C, Darai E. Laparoscopic management of borderline ovarian tumors: results of a French multicenter study. Ann Oncol 2005;16(3):403–10.

  295. Vandenput I, Amant F, Vergote I. Peritoneal recurrences might be less common in advanced stage serous borderline ovarian tumors that were treated by laparotomy. Gynecol Oncol 2005;98(3):523; author reply 4–5.

  296. Siristatidis C, Sergentanis TN, Kanavidis P, Trivella M, Sotiraki M, Mavromatis I, et al. Controlled ovarian hyperstimulation for IVF: impact on ovarian, endometrial and cervical cancer--a systematic review and meta-analysis. Hum Reprod Update 2013;19(2):105–23.

  297. Chan JK, Lin YG, Loizzi V, Ghobriel M, DiSaia PJ, Berman ML. Borderline ovarian tumors in reproductive-age women. Fertility-sparing surgery and outcome. J Reprod Med 2003;48(10):756–60.

  298. Morice P. Borderline tumours of the ovary and fertility. Eur J Cancer 2006;42(2):149–58.

  299. Suh-Burgmann E. Long-term outcomes following conservative surgery for borderline tumor of the ovary: a large population-based study. Gynecol Oncol 2006;103(3):841–7.

  300. Kaern J, Trope CG, Abeler VM. A retrospective study of 370 borderline tumors of the ovary treated at the Norwegian Radium Hospital from 1970 to 1982. A review of clinicopathologic features and treatment modalities. Cancer 1993;71(5):1810–20.

  301. Ortiz BH, Ailawadi M, Colitti C, Muto MG, Deavers M, Silva EG, et al. Second primary or recurrence? Comparative patterns of p53 and K-ras mutations suggest that serous borderline ovarian tumors and subsequent serous carcinomas are unrelated tumors. Cancer Res 2001;61(19):7264–7.

  302. Plaxe SC. Epidemiology of low-grade serous ovarian cancer. Am J Obstet Gynecol 2008;198(4):459.e1-.e4.59E19.

  303. Sherman ME, Mink PJ, Curtis R, Cote TR, Brooks S, Hartge P, et al. Survival among women with borderline ovarian tumors and ovarian carcinoma: a population-based analysis. Cancer 2004;100(5):1045–52.

  304. Muñoz N, Bosch FX, de Sanjosé S, Herrero R, Castellsagué X, Shah KV, et al. Epidemiologic classification of human papillomavirus types associated with cervical cancer. N Engl J Med 2003;348(6):518–27.

  305. Muñoz N, Castellsagué X, de González AB, Gissmann L. Chapter 1: HPV in the etiology of human cancer. Vaccine 2006;24 Suppl 3:S3/1–10.

  306. Stanley M. Pathology and epidemiology of HPV infection in females. Gynecol Oncol 2010;117(2 Suppl):S5–10.

  307. Gravitt PE. The known unknowns of HPV natural history. J Clin Invest 2011;121(12):4593–9.

  308. Schiffman M, Wentzensen N. From human papillomavirus to cervical cancer. Obstet Gynecol 2010;116(1):177–85.

  309. Gadducci A, Barsotti C, Cosio S, Domenici L, Riccardo Genazzani A. Smoking habit, immune suppression, oral contraceptive use, and hormone replacement therapy use and cervical carcinogenesis: a review of the literature. Gynecol Endocrinol 2011;27(8):597–604.

  310. Kjellberg L, Hallmans G, Ahren AM, Johansson R, Bergman F, Wadell G, et al. Smoking, diet, pregnancy and oral contraceptive use as risk factors for cervical intra-epithelial neoplasia in relation to human papillomavirus infection. Br J Cancer 2000;82(7):1332–8.

  311. Vaccarella S, Herrero R, Snijders PJ, Dai M, Thomas JO, Hieu NT, et al. Smoking and human papillomavirus infection: pooled analysis of the International Agency for Research on Cancer HPV Prevalence Surveys. Int J Epidemiol 2008;37(3):536–46.

  312. International Collaboration of Epidemiological Studies of Cervical Cancer, Appleby P, Beral V, Berrington de Gonzalez A, Colin D, Franceschi S, et al. Carcinoma of the cervix and tobacco smoking: collaborative reanalysis of individual data on 13,541 women with carcinoma of the cervix and 23,017 women without carcinoma of the cervix from 23 epidemiological studies. Int J Cancer 2006;118(6):1481–95.

  313. Jordan J, Martin-Hirsch P, Arbyn M, Schenck U, Baldauf JJ, Da Silva D, et al. European guidelines for clinical management of abnormal cervical cytology, part 2. Cytopathology 2009;20(1):5–16.

  314. Dillner J, Kallings I, Brihmer C, Sikström B, Koskela P, Lehtinen M, et al. Seropositivities to human papillomavirus types 16, 18, or 33 capsids and to Chlamydia trachomatis are markers of sexual behavior. J Infect Dis 1996;173(6):1394–8.

  315. de Araujo Souza PS, Sichero L, Maciag PC. HPV variants and HLA polymorphisms: the role of variability on the risk of cervical cancer. Future Oncol 2009;5(3):359–70.

  316. Forman D, de Martel C, Lacey CJ, Soerjomataram I, Lortet-Tieulent J, Bruni L, et al. Global burden of human papillomavirus and related diseases. Vaccine 2012;30 Suppl 5:F12–23.

  317. IARC Working Group on the Evaluation of Carcinogenic Risks to Humans. Human Papillomaviruses. Lyon: IARC; 2007. IARC Monographs on the Evaluation of Carcinogenic Risks to Humans Vol. 90. Tilgjengelig fra: http://monographs.iarc.fr/ENG/Monographs/vol90/mono90.pdf 

  318. Masseundersøkelsen mot livmorhalskreft: årsrapport 2012. Oslo: Kreftregisteret; 2014. Tilgjengelig fra: https://www.kreftregisteret.no/globalassets/publikasjoner-og-rapporter/livmorhalskreft/​aarsrapport_livmorhals_2012.pdf 

  319. Patel S, Liyanage SH, Sahdev A, Rockall AG, Reznek RH. Imaging of endometrial and cervical cancer. Insights into imaging 2010;1(5–6):309–28.

  320. FIGO Committee on Gynecologic Oncology. FIGO staging for carcinoma of the vulva, cervix, and corpus uteri. Int J Gynaecol Obstet 2014;125(2):97–8.

  321. Zaino RJ, Ward S, Delgado G, Bundy B, Gore H, Fetter G, et al. Histopathologic predictors of the behavior of surgically treated stage IB squamous cell carcinoma of the cervix. A Gynecologic Oncology Group study. Cancer 1992;69(7):1750–8.

  322. Young RH, Clement PB. Endocervical adenocarcinoma and its variants: their morphology and differential diagnosis. Histopathology 2002;41(3):185–207.

  323. Bjørge T, Thoresen SO, Skare GB. Incidence, survival and mortality in cervical cancer in Norway, 1956–1990. Eur J Cancer 1993;29a(16):2291–7.

  324. Alfsen GC, Kristensen GB, Skovlund E, Pettersen EO, Abeler VM. Histologic subtype has minor importance for overall survival in patients with adenocarcinoma of the uterine cervix: a population-based study of prognostic factors in 505 patients with nonsquamous cell carcinomas of the cervix. Cancer 2001;92(9):2471–83.

  325. Alfsen GC, Reed W, Abeler VM. Reproducibility of classification in non-squamous cell carcinomas of the uterine cervix. Gynecol Oncol 2003;90(2):282–9.

  326. Soutter WP, Haidopoulos D, Gornall RJ, McIndoe GA, Fox J, Mason WP, et al. Is conservative treatment for adenocarcinoma in situ of the cervix safe? BJOG 2001;108(11):1184–9.

  327. Penson RT, Huang HQ, Wenzel LB, Monk BJ, Stockman S, Long HJ, 3rd, et al. Bevacizumab for advanced cervical cancer: patient-reported outcomes of a randomised, phase 3 trial (NRG Oncology-Gynecologic Oncology Group protocol 240). Lancet Oncol 2015;16(3):301–11.

  328. Peters WA, Liu PY, Barrett RJ, Stock RJ, Monk BJ, Berek JS, et al. Concurrent chemotherapy and pelvic radiation therapy compared with pelvic radiation therapy alone as adjuvant therapy after radical surgery in high-risk early-stage cancer of the cervix. J Clin Oncol 2000;18(8):1606–13.

  329. Martimbeau PW, Kjørstad KE, Kolstad P. Stage IB carcinoma of the cervix, the Norwegian Radium Hospital, 1968–1970: results of treatment and major complications. I. Lymphedema. Am J Obstet Gynecol 1978;131(4):389–94.

  330. Sedlis A, Bundy BN, Rotman MZ, Lentz SS, Muderspach LI, Zaino RJ. A randomized trial of pelvic radiation therapy versus no further therapy in selected patients with stage IB carcinoma of the cervix after radical hysterectomy and pelvic lymphadenectomy: A Gynecologic Oncology Group Study. Gynecol Oncol 1999;73(2):177–83.

  331. Van de Putte G, Lie AK, Vach W, Baekelandt M, Kristensen GB. Risk grouping in stage IB squamous cell cervical carcinoma. Gynecol Oncol 2005;99(1):106–12.

  332. Satoh T, Takei Y, Treilleux I, Devouassoux-Shisheboran M, Ledermann J, Viswanathan AN, et al. Gynecologic Cancer InterGroup (GCIG) consensus review for small cell carcinoma of the cervix. Int J Gynecol Cancer 2014;24(9 Suppl 3):S102–8.

  333. Plante M. Evolution in fertility-preserving options for early-stage cervical cancer: radical trachelectomy, simple trachelectomy, neoadjuvant chemotherapy. Int J Gynecol Cancer 2013;23(6):982–9.

  334. Bouchard-Fortier G, Reade CJ, Covens A. Non-radical surgery for small early-stage cervical cancer. Is it time? Gynecol Oncol 2014;132(3):624–7.

  335. Amant F, Halaska MJ, Fumagalli M, Dahl Steffensen K, Lok C, Van Calsteren K, et al. Gynecologic cancers in pregnancy: guidelines of a second international consensus meeting. Int J Gynecol Cancer 2014;24(3):394–403.

  336. Kucukmetin A, Biliatis I, Naik R, Bryant A. Laparoscopically assisted radical vaginal hysterectomy versus radical abdominal hysterectomy for the treatment of early cervical cancer. Cochrane Database Syst Rev 2013;(10):Cd006651.

  337. Frøding LP, Ottosen C, Mosgaard BJ, Jensen PT. Quality of life, urogynecological morbidity, and lymphedema after radical vaginal trachelectomy for early-stage cervical cancer. Int J Gynecol Cancer 2015;25(4):699–706.

  338. Halaska MJ, Novackova M, Mala I, Pluta M, Chmel R, Stankusova H, et al. A prospective study of postoperative lymphedema after surgery for cervical cancer. Int J Gynecol Cancer 2010;20(5):900–4.

  339. Frøding LP, Ottosen C, Rung-Hansen H, Svane D, Mosgaard BJ, Jensen PT. Sexual functioning and vaginal changes after radical vaginal trachelectomy in early stage cervical cancer patients: a longitudinal study. J Sex Med 2014;11(2):595–604.

  340. Vistad I, Cvancarova M, Fosså SD, Kristensen GB. Postradiotherapy morbidity in long-term survivors after locally advanced cervical cancer: how well do physicians' assessments agree with those of their patients? Int J Radiat Oncol Biol Phys 2008;71(5):1335–42.

  341. Kim JH, Choi JH, Ki EY, Lee SJ, Yoon JH, Lee KH, et al. Incidence and risk factors of lower-extremity lymphedema after radical surgery with or without adjuvant radiotherapy in patients with FIGO stage I to stage IIA cervical cancer. Int J Gynecol Cancer 2012;22(4):686–91.

  342. Vistad I, Cvancarova M, Kristensen GB, Fosså SD. A study of chronic pelvic pain after radiotherapy in survivors of locally advanced cervical cancer. J Cancer Surviv 2011;5(2):208–16.

  343. Vistad I, Kristensen GB, Fosså SD, Dahl AA, Mørkrid L. Intestinal malabsorption in long-term survivors of cervical cancer treated with radiotherapy. Int J Radiat Oncol Biol Phys 2009;73(4):1141–7.

  344. Kristensen GB. Studies on prognostic factors in cervical cancer with special attention to early disease [doktorgrad]. Oslo: University of Oslo; 1999.

  345. Solomon D, Davey D, Kurman R, Moriarty A, O'Connor D, Prey M, et al. The 2001 Bethesda System: terminology for reporting results of cervical cytology. JAMA 2002;287(16):2114–9.

  346. IARC Working Group on the Evaluation of Carcinogenic Risks to Humans. Human Papillomaviruses. I: Biological agents: a review of human carcinogens. Lyon: IARC; 2012. IARC Monographs on the Evaluation of Carcinogenic Risks to Humans Vol. 100 B. s. 255–313. Tilgjengelig fra: https://monographs.iarc.fr/wp-content/uploads/2018/06/mono100B-11.pdf 

  347. Walboomers JM, Jacobs MV, Manos MM, Bosch FX, Kummer JA, Shah KV, et al. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol 1999;189(1):12–9.

  348. Bosch FX, Broker TR, Forman D, Moscicki AB, Gillison ML, Doorbar J, et al. Comprehensive control of human papillomavirus infections and related diseases. Vaccine 2013;31 Suppl 7:H1–31.

  349. Smith JS, Lindsay L, Hoots B, Keys J, Franceschi S, Winer R, et al. Human papillomavirus type distribution in invasive cervical cancer and high-grade cervical lesions: a meta-analysis update. Int J Cancer 2007;121(3):621–32.

  350. Tjalma WA, Fiander A, Reich O, Powell N, Nowakowski AM, Kirschner B, et al. Differences in human papillomavirus type distribution in high-grade cervical intraepithelial neoplasia and invasive cervical cancer in Europe. Int J Cancer 2013;132(4):854–67.

  351. Arbyn M, Tommasino M, Depuydt C, Dillner J. Are 20 human papillomavirus types causing cervical cancer? J Pathol 2014;234(4):431–5.

  352. Castle PE, Schiffman M, Herrero R, Hildesheim A, Rodriguez AC, Bratti MC, et al. A prospective study of age trends in cervical human papillomavirus acquisition and persistence in Guanacaste, Costa Rica. J Infect Dis 2005;191(11):1808–16.

  353. Dillner J, Nygård M, Munk C, Hortlund M, Hansen BT, Lagheden C, et al. Decline of HPV infections in Scandinavian cervical screening populations after introduction of HPV vaccination programs. Vaccine 2018;36(26):3820–9.

  354. Smith JS, Green J, Berrington de Gonzalez A, Appleby P, Peto J, Plummer M, et al. Cervical cancer and use of hormonal contraceptives: a systematic review. Lancet 2003;361(9364):1159–67.

  355. Silins I, Ryd W, Strand A, Wadell G, Tornberg S, Hansson BG, et al. Chlamydia trachomatis infection and persistence of human papillomavirus. Int J Cancer 2005;116(1):110–5.

  356. Leo PJ, Madeleine MM, Wang S, Schwartz SM, Newell F, Pettersson-Kymmer U, et al. Defining the genetic susceptibility to cervical neoplasia-A genome-wide association study. PLoS genetics 2017;13(8):e1006866.

  357. McCredie MR, Sharples KJ, Paul C, Baranyai J, Medley G, Jones RW, et al. Natural history of cervical neoplasia and risk of invasive cancer in women with cervical intraepithelial neoplasia 3: a retrospective cohort study. Lancet Oncol 2008;9(5):425–34.

  358. Castle PE, Schiffman M, Wheeler CM, Solomon D. Evidence for frequent regression of cervical intraepithelial neoplasia-grade 2. Obstet Gynecol 2009;113(1):18–25.

  359. Tainio K, Athanasiou A, Tikkinen KAO, Aaltonen R, Cárdenas J, Hernándes, et al. Clinical course of untreated cervical intraepithelial neoplasia grade 2 under active surveillance: systematic review and meta-analysis. BMJ 2018;360:k499.

  360. Ghaem-Maghami S, Soutter WP. Re: Effect of margin status on cervical intraepithelial neoplasia recurrence following LLETZ in women over 50 years. BJOG 2009;116(3):465.

  361. Kocken M, Helmerhorst TJ, Berkhof J, Louwers JA, Nobbenhuis MA, Bais AG, et al. Risk of recurrent high-grade cervical intraepithelial neoplasia after successful treatment: a long-term multi-cohort study. Lancet Oncol 2011;12(5):441–50.

  362. Paraskevaidis E, Jandial L, Mann EM, Fisher PM, Kitchener HC. Pattern of treatment failure following laser for cervical intraepithelial neoplasia: implications for follow-up protocol. Obstet Gynecol 1991;78(1):80–3.

  363. Arbyn M, Redman CWE, Verdoodt F, Kyrgiou M, Tzafetas M, Ghaem-Maghami S, et al. Incomplete excision of cervical precancer as a predictor of treatment failure: a systematic review and meta-analysis. Lancet Oncol 2017;18(12):1665–79.

  364. Casper GR, Ostor AG, Quinn MA. A clinicopathologic study of glandular dysplasia of the cervix. Gynecol Oncol 1997;64(1):166–70.

  365. Naucler P, Ryd W, Törnberg S, Strand A, Wadell G, Elfgren K, et al. Efficacy of HPV DNA testing with cytology triage and/or repeat HPV DNA testing in primary cervical cancer screening. J Natl Cancer Inst 2009;101(2):88–99.

  366. Mayrand MH, Duarte-Franco E, Rodrigues I, Walter SD, Hanley J, Ferenczy A, et al. Human papillomavirus DNA versus Papanicolaou screening tests for cervical cancer. N Engl J Med 2007;357(16):1579–88.

  367. Gage JC, Hanson VW, Abbey K, Dippery S, Gardner S, Kubota J, et al. Number of cervical biopsies and sensitivity of colposcopy. Obstet Gynecol 2006;108(2):264–72.

  368. Guido R, Schiffman M, Solomon D, Burke L, ASCUS LSIL Triage Study (ALTS) Group. Postcolposcopy management strategies for women referred with low-grade squamous intraepithelial lesions or human papillomavirus DNA-positive atypical squamous cells of undetermined significance: a two-year prospective study. Am J Obstet Gynecol 2003;188(6):1401–5.

  369. Pretorius RG, Belinson JL, Burchette RJ, Hu S, Zhang X, Qiao YL. Regardless of skill, performing more biopsies increases the sensitivity of colposcopy. J Low Genit Tract Dis 2011;15(3):180–8.

  370. Baasland I, Hagen B, Vogt C, Valla M, Romundstad PR. Colposcopy and additive diagnostic value of biopsies from colposcopy-negative areas to detect cervical dysplasia. Acta Obstet Gynecol Scand 2016;95(11):1258–63.

  371. Högberg U, red. Cervixcancerprevention: riktlinjer för utredning, behandling och uppföljning av cervikal intraepitelial neoplasi (CIN). Umå: Svensk Förening för Obstetrik och Gynekologi; 2010. Arbets- och Referensgruppen för Cervixcancerprevention Nr 63 2010. Tilgjengelig fra: https://www.sfog.se/media/18454/intro_arg63_.pdf 

  372. Hunter MI, Monk BJ, Tewari KS. Cervical neoplasia in pregnancy. Part 1: screening and management of preinvasive disease. Am J Obstet Gynecol 2008;199(1):3–9.

  373. Hunter MI, Tewari K, Monk BJ. Cervical neoplasia in pregnancy. Part 2: current treatment of invasive disease. Am J Obstet Gynecol 2008;199(1):10–8.

  374. Nygård M, Daltveit AK, Thoresen SO, Nygard JF. Effect of an antepartum Pap smear on the coverage of a cervical cancer screening programme: a population-based prospective study. BMC Health Serv Res 2007;7:10.

  375. Kärrberg C, Brannstrom M, Strander B, Ladfors L, Rådberg T. Colposcopically directed cervical biopsy during pregnancy; minor surgical and obstetrical complications and high rates of persistence and regression. Acta Obstet Gynecol Scand 2013;92(6):692–9.

  376. Kyrgiou M, Athanasiou A, Paraskevaidi M, Mitra A, Kalliala I, Martin-Hirsch P, et al. Adverse obstetric outcomes after local treatment for cervical preinvasive and early invasive disease according to cone depth: systematic review and meta-analysis. BMJ 2016;354:i3633.

  377. Tatti S, Bornstein J, Prendiville W. Colposcopy: a global perspective: introduction of the new IFCPC colposcopy terminology. Obstet Gynecol Clin North Am 2013;40(2):235–50.

  378. Nøhr B, Tabor A, Frederiksen K, Kjær SK. Loop electrosurgical excision of the cervix and the subsequent risk of preterm delivery. Acta Obstet Gynecol Scand 2007;86(5):596–603.

  379. Sadler L, Saftlas A, Wang W, Exeter M, Whittaker J, McCowan L. Treatment for cervical intraepithelial neoplasia and risk of preterm delivery. JAMA 2004;291(17):2100–6.

  380. Tropé C. En forenklet kolposkopiguide. Gynekologen 2014;27(2):35–40.

  381. Li Z, Zhao C. Long-term follow-up results from women with cervical adenocarcinoma in situ treated by conization: an experience from a large academic women's hospital. J Low Genit Tract Dis 2013;17(4):452–8.

  382. Hagen B, Skjeldestad FE, Bratt H, Tingulstad S, Lie AK. CO2 laser conization for cervical intraepithelial neoplasia grade II-III: complications and efficacy. Acta Obstet Gynecol Scand 1998;77(5):558–63.

  383. Kyrgiou M, Koliopoulos G, Martin-Hirsch P, Arbyn M, Prendiville W, Paraskevaidis E. Obstetric outcomes after conservative treatment for intraepithelial or early invasive cervical lesions: systematic review and meta-analysis. Lancet 2006;367(9509):489–98.

  384. Sjøborg KD, Vistad I, Myhr SS, Svenningsen R, Herzog C, Kloster-Jensen A, et al. Pregnancy outcome after cervical cone excision: a case-control study. Acta Obstet Gynecol Scand 2007;86(4):423–8.

  385. Larsen IK, red. Cancer in Norway 2009: cancer incidence, mortality, survival and prevalence in Norway. Oslo: Cancer Registry of Norway; 2011. Tilgjengelig fra: https://www.kreftregisteret.no/globalassets/publikasjoner-og-rapporter/cancer-in-norway/​cancer_in_norway_2009_and_special_issue.pdf 

  386. Iversen O-E, L.E. E, Baasland I, Kirschner R. Premaligne og maligne forandringer i cervix i graviditet I: Øian P, Jacobsen AF, Kessler J, red. Veileder i fødselshjelp 2014. Oslo: Norsk gynekologisk forening; 2014. Tilgjengelig fra: http://legeforeningen.no/Fagmed/Norsk-gynekologisk-forening/Veiledere/​Veileder-i-fodselshjelp-2014/Premaligne-og-maligne-forandringer-i-cervix-i-graviditet/ 

  387. Kang WD, Choi HS, Kim SM. Is vaccination with quadrivalent HPV vaccine after loop electrosurgical excision procedure effective in preventing recurrence in patients with high-grade cervical intraepithelial neoplasia (CIN2–3)? Gynecol Oncol 2013;130(2):264–8.

  388. Joura EA, Garland SM, Paavonen J, Ferris DG, Perez G, Ault KA, et al. Effect of the human papillomavirus (HPV) quadrivalent vaccine in a subgroup of women with cervical and vulvar disease: retrospective pooled analysis of trial data. BMJ 2012;344:e1401.

  389. Garland SM, Paavonen J, Jaisamrarn U, Naud P, Salmerón J, Chow SN, et al. Prior human papillomavirus-16/18 AS04-adjuvanted vaccination prevents recurrent high grade cervical intraepithelial neoplasia after definitive surgical therapy: Post-hoc analysis from a randomized controlled trial. Int J Cancer 2016;139(12):2812–26.

  390. Sand FL, Kjaer SK, Frederiksen K, Dehlendorff C. Risk of cervical intraepithelial neoplasia grade 2 or worse after conization in relation to HPV vaccination status. Int J Cancer 2019;Oct 24 [Epub ahead of print].

  391. Joura EA, Kyrgiou M, Bosch FX, Kesic V, Niemenen P, Redman CW, et al. Human papillomavirus vaccination: The ESGO-EFC position paper of the European society of Gynaecologic Oncology and the European Federation for colposcopy. Eur J Cancer 2019;116:21–6.

  392. Nasjonal oppfølging av vaksinasjons-programmet for HPV [nettdokument]. Oslo: Folkehelseinstituttet [oppdatert 02. jan 2020; lest 21. jan 2020]. Tilgjengelig fra: https://www.fhi.no/studier/hpv-oppfolging/ 

  393. Overvåking av HPV i Meldingssystemet for smittsomme sykdommer (MSIS) [nettdokument]. Oslo: Folkehelseinstituttet [oppdatert 30. okto 2018; lest 21. jan 2020]. Tilgjengelig fra: https://www.fhi.no/hn/helseregistre-og-registre/msis/msis-biobank/hpv-i-msis/ 

  394. Lehtinen M, Paavonen J, Wheeler CM, Jaisamrarn U, Garland SM, Castellsagué X, et al. Overall efficacy of HPV-16/18 AS04-adjuvanted vaccine against grade 3 or greater cervical intraepithelial neoplasia: 4-year end-of-study analysis of the randomised, double-blind PATRICIA trial. Lancet Oncol 2012;13(1):89–99.

  395. Huh WK, Joura EA, Giuliano AR, Iversen OE, de Andrade RP, Ault KA, et al. Final efficacy, immunogenicity, and safety analyses of a nine-valent human papillomavirus vaccine in women aged 16–26 years: a randomised, double-blind trial. Lancet 2017;390(10108):2143–59.

  396. Kavanagh K, Pollock KG, Cuschieri K, Palmer T, Cameron RL, Watt C, et al. Changes in the prevalence of human papillomavirus following a national bivalent human papillomavirus vaccination programme in Scotland: a 7-year cross-sectional study. Lancet Infect Dis 2017;17(12):1293–302.

  397. Garland SM, Kjaer SK, Muñoz N, Block SL, Brown DR, DiNubile MJ, et al. Impact and Effectiveness of the Quadrivalent Human Papillomavirus Vaccine: A Systematic Review of 10 Years of Real-world Experience. Clin Infect Dis 2016;63(4):519–27.

  398. Pollock K. The impact of the HPV vaccine in Scotland. Foredrag på HPV Conference; Ashling Hotel in Dublin mai 2017. Tilgjengelig fra: https://www.hse.ie/eng/health/immunisation/hcpinfo/conference/hpv173.pdf 

  399. Statistikk for HPV-vaksinasjon i barnevaksinasjonsprogrammet [nettdokument]. Oslo: Folkehelseinstituttet [oppdatert 21. mai 2019; lest 21. jan 2020]. Tilgjengelig fra: https://www.fhi.no/hn/helseregistre-og-registre/sysvak/dekkningsstatistikk/ 

  400. Bowring J, Strander B, Young M, Evans H, Walker P. The Swede score: evaluation of a scoring system designed to improve the predictive value of colposcopy. J Low Genit Tract Dis 2010;14(4):301–5.

  401. Howe HL, Wingo PA, Thun MJ, Ries LA, Rosenberg HM, Feigal EG, et al. Annual report to the nation on the status of cancer (1973 through 1998), featuring cancers with recent increasing trends. J Natl Cancer Inst 2001;93(11):824–42.

  402. Iversen T, Tretli S. Intraepithelial and invasive squamous cell neoplasia of the vulva: trends in incidence, recurrence, and survival rate in Norway. Obstet Gynecol 1998;91(6):969–72.

  403. Lai KW, Mercurio MG. Medical and surgical approaches to vulvar intraepithelial neoplasia. Dermatol Ther 2010;23(5):477–84.

  404. Schuurman MS, van den Einden LC, Massuger LF, Kiemeney LA, van der Aa MA, de Hullu JA. Trends in incidence and survival of Dutch women with vulvar squamous cell carcinoma. Eur J Cancer 2013;49(18):3872–80.

  405. Kumar S, Shah JP, Malone JM, Jr. Vulvar cancer in women less than fifty in United States, 1980–2005. Gynecol Oncol 2009;112(1):283–4; author reply 34.

     

  406. Meltzer-Gunnes CJ, Smastuen MC, Kristensen GB, Trope CG, Lie AK, Vistad I. Vulvar carcinoma in Norway: A 50-year perspective on trends in incidence, treatment and survival. Gynecol Oncol 2017;145(3):543–8.

  407. De Hullu JA, Hollema H, Lolkema S, Boezen M, Boonstra H, Burger MP, et al. Vulvar carcinoma. The price of less radical surgery. Cancer 2002;95(11):2331–8.

  408. Jones RW, Rowan DM. Vulvar intraepithelial neoplasia III: a clinical study of the outcome in 113 cases with relation to the later development of invasive vulvar carcinoma. Obstet Gynecol 1994;84(5):741–5.

  409. de Hullu JA, van der Avoort IA, Oonk MH, van der Zee AG. Management of vulvar cancers. Eur J Surg Oncol 2006;32(8):825–31.

  410. Micheletti L, Preti M. Surgery of the vulva in vulvar cancer. Best Pract Res Clin Obstet Gynaecol 2014;28(7):1074–87.

  411. Iversen T, Abeler V, Aalders J. Individualized treatment of stage I carcinoma of the vulva. Obstet Gynecol 1981;57(1):85–9.

  412. Scheistrøen M, Nesland JM, Trope C. Have patients with early squamous carcinoma of the vulva been overtreated in the past? The Norwegian experience 1977–1991. Eur J Gynaecol Oncol 2002;23(2):93–103.

     

  413. Woelber L, Kock L, Gieseking F, Petersen C, Trillsch F, Choschzick M, et al. Clinical management of primary vulvar cancer. Eur J Cancer 2011;47(15):2315–21.

  414. Dhakal HP, Nesland JM, Førsund M, Trope CG, Holm R. Primary tumor vascularity, HIF-1alpha and VEGF expression in vulvar squamous cell carcinomas: their relationships with clinicopathological characteristics and prognostic impact. BMC Cancer 2013;13:506.

  415. Knopp S. Prognostic studies in vulvar squamous cell carcinoma: with emphasis on cell cycle components, human papillomavirus and occult metastases [doktorgrad]. Oslo: University of Oslo; 2006. Series of dissertations submitted to the Faculty of Medicine, University of Oslo No. 492.

  416. FIGO (International Federation of Gynecology and Obstetrics) 26th Annual Report on the Results of Treatment in Gynecological Cancer. Int J Gynaecol Obstet 2006;95 Suppl 1:S1–257.

  417. Beller U, Quinn MA, Benedet JL, Creasman WT, Ngan HY, Maisonneuve P, et al. Carcinoma of the vulva. FIGO 26th Annual Report on the Results of Treatment in Gynecological Cancer. Int J Gynaecol Obstet 2006;95 Suppl 1:S7–27.

  418. Smith JS, Backes DM, Hoots BE, Kurman RJ, Pimenta JM. Human papillomavirus type-distribution in vulvar and vaginal cancers and their associated precursors. Obstet Gynecol 2009;113(4):917–24.

  419. Srodon M, Stoler MH, Baber GB, Kurman RJ. The distribution of low and high-risk HPV types in vulvar and vaginal intraepithelial neoplasia (VIN and VaIN). Am J Surg Pathol 2006;30(12):1513–8.

  420. Cancer Facts & Figures 2013. Atlanta: American Cancer Society; 2013. Tilgjengelig fra: http://www.cancer.org/acs/groups/content/@epidemiologysurveilance/documents/document/acspc-036845.pdf 

  421. Edey KA, Allan E, Murdoch JB, Cooper S, Bryant A. Interventions for the treatment of Paget's disease of the vulva. Cochrane Database Syst Rev 2013;(10):Cd009245.

  422. Ansink A, van der Velden J. Surgical interventions for early squamous cell carcinoma of the vulva. Cochrane Database Syst Rev 2000;(2):Cd002036.

  423. Chan JK, Sugiyama V, Pham H, Gu M, Rutgers J, Osann K, et al. Margin distance and other clinico-pathologic prognostic factors in vulvar carcinoma: a multivariate analysis. Gynecol Oncol 2007;104(3):636–41.

  424. Aviki EM, Esselen KM, Barcia SM, Nucci MR, Horowitz NS, Feltmate CM, et al. Does plastic surgical consultation improve the outcome of patients undergoing radical vulvectomy for squamous cell carcinoma of the vulva? Gynecol Oncol 2015;137(1):60–5.

  425. de Hullu JA, van der Zee AG. Surgery and radiotherapy in vulvar cancer. Crit Rev Oncol Hematol 2006;60(1):38–58.

  426. Woelber L, Choschzick M, Eulenburg C, Hager M, Jaenicke F, Gieseking F, et al. Prognostic value of pathological resection margin distance in squamous cell cancer of the vulva. Ann Surg Oncol 2011;18(13):3811–8.

  427. Micheletti L, Bogliatto F, Levi AC. La linfoadenectomia inguino-femorale: fondamenti embriologici, anatomotopografici, anatomochirurgici sulla preservazione della fascia femorale. Roma: CIC Edizioni Internazionali; 2005.

  428. van der Velden J, Fons G, Lawrie TA. Primary groin irradiation versus primary groin surgery for early vulvar cancer. Cochrane Database Syst Rev 2011;(5):CD002224.

  429. Oonk MH, van Hemel BM, Hollema H, de Hullu JA, Ansink AC, Vergote I, et al. Size of sentinel-node metastasis and chances of non-sentinel-node involvement and survival in early stage vulvar cancer: results from GROINSS-V, a multicentre observational study. Lancet Oncol 2010;11(7):646–52.

  430. Robison K, Roque D, McCourt C, Stuckey A, DiSilvestro PA, Sung CJ, et al. Long-term follow-up of vulvar cancer patients evaluated with sentinel lymph node biopsy alone. Gynecol Oncol 2014;133(3):416–20.

  431. Levenback C, van der Zee AGJ, Coleman R, red. Clinical lymphatic mapping in gynecologic cancers. London and New York: Taylor & Francis; 2004.

  432. Coleman RL, Ali S, Levenback CF, Gold MA, Fowler JM, Judson PL, et al. Is bilateral lymphadenectomy for midline squamous carcinoma of the vulva always necessary? An analysis from Gynecologic Oncology Group (GOG) 173. Gynecol Oncol 2013;128(2):155–9.

  433. Hauspy J, Beiner M, Harley I, Ehrlich L, Rasty G, Covens A. Sentinel lymph node in vulvar cancer. Cancer 2007;110(5):1015–23.

  434. Levenback C, Coleman RL, Burke TW, Bodurka-Bevers D, Wolf JK, Gershenson DM. Intraoperative lymphatic mapping and sentinel node identification with blue dye in patients with vulvar cancer. Gynecol Oncol 2001;83(2):276–81.

  435. Lawrie TA, Patel A, Martin-Hirsch PP, Bryant A, Ratnavelu ND, Naik R, et al. Sentinel node assessment for diagnosis of groin lymph node involvement in vulval cancer. Cochrane Database Syst Rev 2014;(6):CD010409.

  436. Levenback CF, Ali S, Coleman RL, Gold MA, Fowler JM, Judson PL, et al. Lymphatic mapping and sentinel lymph node biopsy in women with squamous cell carcinoma of the vulva: a gynecologic oncology group study. J Clin Oncol 2012;30(31):3786–91.

  437. Stehman FB, Bundy BN, Thomas G, Varia M, Okagaki T, Roberts J, et al. Groin dissection versus groin radiation in carcinoma of the vulva: a Gynecologic Oncology Group study. Int J Radiat Oncol Biol Phys 1992;24(2):389–96.

  438. Pouwer AW, Hinten F, van der Velden J, Smolders RGV, Slangen BFM, Zijlmans H, et al. Volume-controlled versus short drainage after inguinofemoral lymphadenectomy in vulvar cancer patients: A Dutch nationwide prospective study. Gynecol Oncol 2017;146(3):580–7.

  439. Oonk MHM, Planchamp F, Baldwin P, Bidzinski M, Brannstrom M, Landoni F, et al. European Society of Gynaecological Oncology Guidelines for the Management of Patients With Vulvar Cancer. Int J Gynecol Cancer 2017;27(4):832–7.

  440. Mahner S, Jueckstock JK, Hilpert F, Lubbe D, Harter P, De Gregorio N, et al. Impact of adjuvant therapy in lymph-node positive vulvar cancer: The AGO CARE 1 study. J Clin Oncol 2012;30(15 SUPPL. 1):abstract 5007.

  441. Gaarenstroom KN, Kenter GG, Trimbos JB, Agous I, Amant F, Peters AA, et al. Postoperative complications after vulvectomy and inguinofemoral lymphadenectomy using separate groin incisions. Int J Gynecol Cancer 2003;13(4):522–7.

  442. Larson B, Tholander B, red. Björkholm E. Vulvacancer. Stockholm: Svenska läkaresällskapet; 2000. Rapport / Svensk förenings för obstetrik och gynekologi arbets- och referensgrupp nr. 44.

  443. Judson PL, Habermann EB, Baxter NN, Durham SB, Virnig BA. Trends in the incidence of invasive and in situ vulvar carcinoma. Obstet Gynecol 2006;107(5):1018–22.

  444. Kokka F, Singh N, Faruqi A, Gibbon K, Rosenthal AN. Is differentiated vulval intraepithelial neoplasia the precursor lesion of human papillomavirus-negative vulval squamous cell carcinoma? Int J Gynecol Cancer 2011;21(7):1297–305.

  445. Jones RW, Rowan DM, Stewart AW. Vulvar intraepithelial neoplasia: aspects of the natural history and outcome in 405 women. Obstet Gynecol 2005;106(6):1319–26.

  446. van Seters M, van Beurden M, de Craen AJ. Is the assumed natural history of vulvar intraepithelial neoplasia III based on enough evidence? A systematic review of 3322 published patients. Gynecol Oncol 2005;97(2):645–51.

  447. Holschneider CH. Vulvar intraepithial neoplasia. UpToDate [database]. Waltham, MA: UoToDate, Inc [oppdatert 7. november 2014; lest 23. juni 2016].

  448. Terlou A, Blok LJ, Helmerhorst TJ, van Beurden M. Premalignant epithelial disorders of the vulva: squamous vulvar intraepithelial neoplasia, vulvar Paget's disease and melanoma in situ. Acta Obstet Gynecol Scand 2010;89(6):741–8.

  449. Jones RW. Vulval intraepithelial neoplasia: current perspectives. Eur J Gynaecol Oncol 2001;22(6):393–402.

  450. Preti M, Van Seters M, Sideri M, Van Beurden M. Squamous vulvar intraepithelial neoplasia. Clin Obstet Gynecol 2005;48(4):845–61.

  451. Hørding U, Junge J, Poulsen H, Lundvall F. Vulvar intraepithelial neoplasia III: a viral disease of undetermined progressive potential. Gynecol Oncol 1995;56(2):276–9.

  452. Ferris DG, Cox JT, O'Connor DM, Wright VC, Foerster J. Modern colposcopy: textbook and atlas. 2. utg. Dubuque, Iowa: Kendall/Hunt; 2004.

  453. Muñoz N, Kjaer SK, Sigurdsson K, Iversen OE, Hernandez-Avila M, Wheeler CM, et al. Impact of human papillomavirus (HPV)-6/11/16/18 vaccine on all HPV-associated genital diseases in young women. J Natl Cancer Inst 2010;102(5):325–39.

  454. Hampl M, Sarajuuri H, Wentzensen N, Bender HG, Kueppers V. Effect of human papillomavirus vaccines on vulvar, vaginal, and anal intraepithelial lesions and vulvar cancer. Obstet Gynecol 2006;108(6):1361–8.

  455. Kenter GG, Welters MJ, Valentijn AR, Lowik MJ, Berends-van der Meer DM, Vloon AP, et al. Vaccination against HPV-16 oncoproteins for vulvar intraepithelial neoplasia. N Engl J Med 2009;361(19):1838–47.

  456. Clinical Effectiveness Group, British Association for Sexual Health and HIV. 2014 UK national guideline on the management of vulval conditions. London: British Association for Sexual Health and HIV; 2014. Tilgjengelig fra: http://www.bashh.org/documents/UK%20national%20guideline%20for%20the%20management%20of%20vulval%20conditions%202014.pdf 

  457. Pepas L, Kaushik S, Nordin A, Bryant A, Lawrie TA. Medical interventions for high-grade vulval intraepithelial neoplasia. Cochrane Database Syst Rev 2015;(8):Cd007924.

  458. Berkowitz RS, Goldstein DP. Gestational Trophoblastic Neoplasia. I: Berek JS, Hacker NF, red. Practical gynecologic oncology. 2. utg. Baltimore: Williams & Wilkins; 1994. s. 457–78.

  459. Hancock BW, Seckl MJ, Berkowitz RS, red. Gestational trophoblastic disease. 4. utg. [s.l.]: International Society for the Study of Trophoblastic Diseases; 2015. Tilgjengelig fra: http://isstd.org/gtd-book/front-page/ 

  460. Soper JT, Lewis Jr JL, Hammond C. Gestational Trophoblastic Disease. I: Hoskins WJ, Perez CA, Toung R, red. Principles and practice of gynecologic oncology. 4 utg. Philadelphia: Lippincott Williams & Wilkins; 2005. s. 1039–77.

  461. Kohorn EI. The trophoblastic Tower of Babel: classification systems for metastatic gestational trophoblastic neoplasia. Gynecol Oncol 1995;56(2):280–8.

  462. Gamer EI, Garrett A, Goldstein DP, Berkowitz RS. Significance of chest computed tomography findings in the evaluation and treatment of persistent gestational trophoblastic neoplasia. J Reprod Med 2004;49(6):411–4.

  463. Goldstein DP, Berkowitz RS. Management of molar pregnancy and gestational trophoblastic neoplasms. I: Peltecu GC, Tropé CG, red. Gynecol Oncol. Bucharest Publishing House of the Romanian Academy; 2010. s. 483–94.

  464. Seckl MJ, Sebire NJ, Berkowitz RS. Gestational trophoblastic disease. Lancet 2010;376(9742):717–29.

  465. Osborne RJ, Filiaci V, Schink JC, Mannel RS, Alvarez Secord A, Kelley JL, et al. Phase III trial of weekly methotrexate or pulsed dactinomycin for low-risk gestational trophoblastic neoplasia: a gynecologic oncology group study. J Clin Oncol 2011;29(7):825–31.

  466. May T, Goldstein DP, Berkowitz RS. Current chemotherapeutic management of patients with gestational trophoblastic neoplasia. Chemotherapy research and practice 2011;2011:806256.

  467. Kohorn EI. Evaluation of the criteria used to make the diagnosis of nonmetastatic gestational trophoblastic neoplasia. Gynecol Oncol 1993;48(2):139–47.

  468. Oncolex, Onkologisk oppslagsverk [database]. Oslo: Oslo universitetssykehus HF [oppdatert 2016; lest 23. juni 2016]. Tilgjengelig fra: http://oncolex.no/ 

  469. Lurain JR, Singh DK, Schink JC. Role of surgery in the management of high-risk gestational trophoblastic neoplasia. J Reprod Med 2006;51(10):773–6.

  470. Baergen RN, Rutgers JL, Young RH, Osann K, Scully RE. Placental site trophoblastic tumor: A study of 55 cases and review of the literature emphasizing factors of prognostic significance. Gynecol Oncol 2006;100(3):511–20.

  471. Palmer JE, Macdonald M, Wells M, Hancock BW, Tidy JA. Epithelioid trophoblastic tumor: a review of the literature. J Reprod Med 2008;53(7):465–75.

  472. Nasjonal helseplan (2007–2010). Oslo: Helse- og omsorgsdepartementet; 2006. Særtrykk av St.prp. nr. 1 (2006–2007) kapittel 6. Tilgjengelig fra: https://www.regjeringen.no/globalassets/upload/HOD/Sykehus/Nasjonal_helseplan_Sartrykk.pdf 

  473. Lov om kommunale helse- og omsorgstjenester m.m. (helse- og omsorgstjenesteloven). LOV-2011-06-24-30.

  474. Veileder i onkologisk gynekologi 2002. Oslo: Norsk gynekologisk forening; 2002. Tilgjengelig fra: http://legeforeningen.no/Fagmed/Norsk-gynekologisk-forening/Veiledere/veileder-i-onkologisk-gynekologi-2002/ 

  475. Sammen mot kreft: nasjonal kreftstrategi 2013–2017. Oslo: Helse- og omsorgsdepartementet; 2013. Tilgjengelig fra: https://www.regjeringen.no/contentassets/07cd14ff763444a3997de1570b85fad1/​kreftstrategien_2013.pdf.